{
  "model": "chatgpt-gpt-5.3-codex-spark",
  "taskId": "tumor-vaccine-ici",
  "runIndex": 1,
  "result": {
    "text": "- [x] `output/study_overview.json`  \n- [x] `output/quantitative_findings.json`  \n- [x] `output/claim_audit.json`  \n- [x] `output/public_summary.json`",
    "thoughts": "",
    "steps": [
      {
        "step": 1,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "list_directory",
            "input": {
              "dir_path": ".",
              "ignore": [
                ".git"
              ],
              "file_filtering_options": {
                "respect_git_ignore": true,
                "respect_gemini_ignore": true
              }
            },
            "output": "input/\noutput/\nschemas/\nTASK.md",
            "callId": "call_fKGDCuhppqH8qMmzItl1imTo"
          }
        ],
        "usage": {
          "promptTokens": 571,
          "cachedTokens": 0,
          "responseTokens": 46,
          "thinkingTokens": 70,
          "totalTokens": 687
        },
        "costUsd": 0.00037475
      },
      {
        "step": 2,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "TASK.md",
              "offset": 0,
              "limit": 400
            },
            "output": "L1: # Agent Task\nL2: \nL3: Task id: tumor-vaccine-ici\nL4: Task title: mRNA tumor sensitization for checkpoint blockade\nL5: Reference paper: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\nL6: Reference URL: https://www.nature.com/articles/s41586-025-09006-8\nL7: \nL8: ## Objective\nL9: Read the report and produce all required JSON outputs that satisfy their schemas.\nL10: \nL11: ## Inputs On Disk\nL12: - Report: `input/report.md`\nL13: - Schemas: in `schemas/`\nL14: \nL15: ## Required Outputs\nL16: - `output/study_overview.json` (schema: `schemas/study_overview.schema.json`)\nL17: - `output/quantitative_findings.json` (schema: `schemas/quantitative_findings.schema.json`)\nL18: - `output/claim_audit.json` (schema: `schemas/claim_audit.schema.json`)\nL19: - `output/public_summary.json` (schema: `schemas/public_summary.schema.json`)\nL20: \nL21: ## Constraints\nL22: - Do not invent source facts; derive calculations only from values in the report.\nL23: - Use line refs as `L<number>` where required.\nL24: - Where quotes are required, copy exact report snippets.\nL25: - For calculation outputs, line_refs must include every report line used for equations, constants, and numeric substitutions.\nL26: - Use relative paths only.\nL27: - Never use absolute paths.\nL28: - Never use `..` in paths.\nL29: - Write valid JSON only.\nL30: \nL31: ## Completion\nL32: Respond with a checklist of written output files.\nL33: After the checklist, stop. Do not call more tools.",
            "callId": "call_mL24lKmYVaTrwEaPiGM60FN4"
          }
        ],
        "usage": {
          "promptTokens": 634,
          "cachedTokens": 0,
          "responseTokens": 30,
          "thinkingTokens": 53,
          "totalTokens": 717
        },
        "costUsd": 0.00032450000000000003
      },
      {
        "step": 3,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "list_directory",
            "input": {
              "dir_path": "input",
              "ignore": [
                ".git"
              ],
              "file_filtering_options": {
                "respect_git_ignore": true,
                "respect_gemini_ignore": true
              }
            },
            "output": "report.md",
            "callId": "call_H1QHG3TvqRMztaObsi6b5yDB"
          },
          {
            "toolName": "list_directory",
            "input": {
              "dir_path": "schemas",
              "ignore": [
                ".git"
              ],
              "file_filtering_options": {
                "respect_git_ignore": true,
                "respect_gemini_ignore": true
              }
            },
            "output": "claim_audit.schema.json\npublic_summary.schema.json\nquantitative_findings.schema.json\nstudy_overview.schema.json",
            "callId": "call_iuBOpFEvLBVNgtqhdJWCyPUN"
          }
        ],
        "usage": {
          "promptTokens": 1084,
          "cachedTokens": 0,
          "responseTokens": 103,
          "thinkingTokens": 39,
          "totalTokens": 1226
        },
        "costUsd": 0.0005549999999999999
      },
      {
        "step": 4,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "input/report.md",
              "offset": 0,
              "limit": 400
            },
            "output": "L1: # Structured Paper Report: Tumor Sensitization by mRNA Vaccination\nL2: \nL3: ## Citation\nL4: - Title: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\nL5: - Journal: Nature\nL6: - Year: 2025\nL7: - DOI: 10.1038/s41586-025-09006-8\nL8: - Source URL: https://www.nature.com/articles/s41586-025-09006-8\nL9: \nL10: ## One-Paragraph Context\nL11: Immune checkpoint inhibitors (ICIs) can produce durable responses in some cancers, but many tumors remain non-responsive due to weak antigen presentation or poor immune priming. The paper investigates whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy.\nL12: \nL13: ## Study Design Snapshot\nL14: - Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\nL15: - Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\nL16: - Mechanistic probes: immunopeptidomics, transcriptomics, and perturbation controls (including IFNAR1 blockade and non-mRNA particle controls).\nL17: \nL18: ## Cohorts and Scenarios\nL19: 1. Mouse efficacy cohort (combination therapy): 78 tumor-bearing mice pooled across repeat experiments.\nL20: 2. Mouse control cohort (vaccine only, ICI only, and vehicle): 84 tumor-bearing mice pooled across matched controls.\nL21: 3. Human retrospective metastatic cohort: 130 patients total.\nL22: 4. Human vaccinated subgroup: 43 patients.\nL23: 5. Human unvaccinated subgroup: 87 patients.\nL24: \nL25: ## Quantitative Findings\nL26: | Metric | Vaccine/Combination Arm | Comparator | Interpretation |\nL27: |---|---:|---:|---|\nL28: | Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |\nL29: | Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |\nL30: | Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |\nL31: | Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |\nL32: | PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable |\nL33: | Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy |\nL34: \nL35: ## Controls and Null/Conditional Results\nL36: - Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\nL37: - ICI-only treatment had limited activity in low-immunogenic baseline settings.\nL38: - Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\nL39: - Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\nL40: \nL41: ## Mechanistic Chain Proposed by Authors\nL42: 1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\nL43: 2. Interferon-associated antigen processing and presentation pathways increase.\nL44: 3. A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\nL45: 4. PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\nL46: 5. Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\nL47: \nL48: ## Caveats and Threats to Validity\nL49: - The human analysis is retrospective and non-randomized; residual confounding is likely.\nL50: - Vaccination timing relative to ICI initiation varied across patients.\nL51: - Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\nL52: - Mouse model effects may not map one-to-one to all human tumors.\nL53: - Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\nL54: \nL55: ## Practical Takeaway\nL56: The study supports a biologically coherent hypothesis that intratumoral mRNA vaccination can prime tumors for stronger ICI responses, but prospective randomized studies are required before clinical protocol changes are justified.",
            "callId": "call_K2nLERB2lKLnn1ZaQ3oIKuDN"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/study_overview.schema.json",
              "offset": 0,
              "limit": 400
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-study_overview\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"paper\": {\nL7:       \"type\": \"object\",\nL8:       \"properties\": {\nL9:         \"title\": {\nL10:           \"type\": \"string\",\nL11:           \"minLength\": 10\nL12:         },\nL13:         \"doi\": {\nL14:           \"type\": \"string\",\nL15:           \"pattern\": \"^10\\\\.\"\nL16:         },\nL17:         \"publication_year\": {\nL18:           \"type\": \"integer\",\nL19:           \"minimum\": 1900,\nL20:           \"maximum\": 2100\nL21:         },\nL22:         \"domain\": {\nL23:           \"type\": \"string\",\nL24:           \"enum\": [\nL25:             \"oncology-immunology\",\nL26:             \"exoplanet-atmospheres\",\nL27:             \"climate-science\",\nL28:             \"neuroscience\",\nL29:             \"other\"\nL30:           ]\nL31:         },\nL32:         \"study_type\": {\nL33:           \"type\": \"string\",\nL34:           \"enum\": [\nL35:             \"preclinical+retrospective\",\nL36:             \"observational-astronomy\",\nL37:             \"randomized-trial\",\nL38:             \"simulation\",\nL39:             \"mixed\"\nL40:           ]\nL41:         }\nL42:       },\nL43:       \"required\": [\nL44:         \"title\",\nL45:         \"doi\",\nL46:         \"publication_year\",\nL47:         \"domain\",\nL48:         \"study_type\"\nL49:       ],\nL50:       \"additionalProperties\": false\nL51:     },\nL52:     \"core_question\": {\nL53:       \"type\": \"string\",\nL54:       \"minLength\": 20\nL55:     },\nL56:     \"datasets_or_cohorts\": {\nL57:       \"type\": \"array\",\nL58:       \"items\": {\nL59:         \"type\": \"object\",\nL60:         \"properties\": {\nL61:           \"id\": {\nL62:             \"type\": \"string\",\nL63:             \"pattern\": \"^[a-z0-9-]+$\"\nL64:           },\nL65:           \"label\": {\nL66:             \"type\": \"string\",\nL67:             \"minLength\": 3\nL68:           },\nL69:           \"sample_size_or_observations\": {\nL70:             \"type\": \"string\",\nL71:             \"minLength\": 1\nL72:           },\nL73:           \"description\": {\nL74:             \"type\": \"string\",\nL75:             \"minLength\": 20\nL76:           }\nL77:         },\nL78:         \"required\": [\nL79:           \"id\",\nL80:           \"label\",\nL81:           \"sample_size_or_observations\",\nL82:           \"description\"\nL83:         ],\nL84:         \"additionalProperties\": false\nL85:       },\nL86:       \"minItems\": 2,\nL87:       \"maxItems\": 8\nL88:     },\nL89:     \"major_limitations\": {\nL90:       \"type\": \"array\",\nL91:       \"items\": {\nL92:         \"type\": \"string\",\nL93:         \"minLength\": 12\nL94:       },\nL95:       \"minItems\": 3,\nL96:       \"maxItems\": 8\nL97:     }\nL98:   },\nL99:   \"required\": [\nL100:     \"paper\",\nL101:     \"core_question\",\nL102:     \"datasets_or_cohorts\",\nL103:     \"major_limitations\"\nL104:   ],\nL105:   \"additionalProperties\": false\nL106: }",
            "callId": "call_fdrGJyiAExsOuryD6mzssOCb"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/quantitative_findings.schema.json",
              "offset": 0,
              "limit": 400
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-quantitative_findings\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"findings\": {\nL7:       \"type\": \"array\",\nL8:       \"items\": {\nL9:         \"type\": \"object\",\nL10:         \"properties\": {\nL11:           \"id\": {\nL12:             \"type\": \"string\",\nL13:             \"pattern\": \"^Q[0-9]{2}$\"\nL14:           },\nL15:           \"metric\": {\nL16:             \"type\": \"string\",\nL17:             \"minLength\": 6\nL18:           },\nL19:           \"value\": {\nL20:             \"type\": \"string\",\nL21:             \"minLength\": 1\nL22:           },\nL23:           \"comparator_or_baseline\": {\nL24:             \"type\": \"string\",\nL25:             \"minLength\": 1\nL26:           },\nL27:           \"interpretation\": {\nL28:             \"type\": \"string\",\nL29:             \"minLength\": 12\nL30:           },\nL31:           \"evidence_line_refs\": {\nL32:             \"type\": \"array\",\nL33:             \"items\": {\nL34:               \"type\": \"string\",\nL35:               \"pattern\": \"^L[1-9]\\\\d*$\"\nL36:             },\nL37:             \"minItems\": 1,\nL38:             \"maxItems\": 3\nL39:           }\nL40:         },\nL41:         \"required\": [\nL42:           \"id\",\nL43:           \"metric\",\nL44:           \"value\",\nL45:           \"comparator_or_baseline\",\nL46:           \"interpretation\",\nL47:           \"evidence_line_refs\"\nL48:         ],\nL49:         \"additionalProperties\": false\nL50:       },\nL51:       \"minItems\": 5,\nL52:       \"maxItems\": 14\nL53:     },\nL54:     \"controls_or_null_results\": {\nL55:       \"type\": \"array\",\nL56:       \"items\": {\nL57:         \"type\": \"object\",\nL58:         \"properties\": {\nL59:           \"statement\": {\nL60:             \"type\": \"string\",\nL61:             \"minLength\": 10\nL62:           },\nL63:           \"evidence_line_ref\": {\nL64:             \"$ref\": \"#/definitions/schemas-quantitative_findings/properties/findings/items/properties/evidence_line_refs/items\"\nL65:           }\nL66:         },\nL67:         \"required\": [\nL68:           \"statement\",\nL69:           \"evidence_line_ref\"\nL70:         ],\nL71:         \"additionalProperties\": false\nL72:       },\nL73:       \"minItems\": 2,\nL74:       \"maxItems\": 10\nL75:     }\nL76:   },\nL77:   \"required\": [\nL78:     \"findings\",\nL79:     \"controls_or_null_results\"\nL80:   ],\nL81:   \"additionalProperties\": false\nL82: }",
            "callId": "call_LIMLvt1TzEeKy31qhrf5Cx4i"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/claim_audit.schema.json",
              "offset": 0,
              "limit": 400
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-claim_audit\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"claims\": {\nL7:       \"type\": \"array\",\nL8:       \"items\": {\nL9:         \"type\": \"object\",\nL10:         \"properties\": {\nL11:           \"claim_id\": {\nL12:             \"type\": \"string\",\nL13:             \"pattern\": \"^C[0-9]{2}$\"\nL14:           },\nL15:           \"claim\": {\nL16:             \"type\": \"string\",\nL17:             \"minLength\": 20\nL18:           },\nL19:           \"strength\": {\nL20:             \"type\": \"string\",\nL21:             \"enum\": [\nL22:               \"strong\",\nL23:               \"moderate\",\nL24:               \"tentative\"\nL25:             ]\nL26:           },\nL27:           \"evidence\": {\nL28:             \"type\": \"array\",\nL29:             \"items\": {\nL30:               \"type\": \"object\",\nL31:               \"properties\": {\nL32:                 \"quote\": {\nL33:                   \"type\": \"string\",\nL34:                   \"minLength\": 10\nL35:                 },\nL36:                 \"line_ref\": {\nL37:                   \"type\": \"string\",\nL38:                   \"pattern\": \"^L[1-9]\\\\d*$\"\nL39:                 }\nL40:               },\nL41:               \"required\": [\nL42:                 \"quote\",\nL43:                 \"line_ref\"\nL44:               ],\nL45:               \"additionalProperties\": false\nL46:             },\nL47:             \"minItems\": 2,\nL48:             \"maxItems\": 3\nL49:           },\nL50:           \"caveat\": {\nL51:             \"type\": \"string\",\nL52:             \"minLength\": 20\nL53:           }\nL54:         },\nL55:         \"required\": [\nL56:           \"claim_id\",\nL57:           \"claim\",\nL58:           \"strength\",\nL59:           \"evidence\",\nL60:           \"caveat\"\nL61:         ],\nL62:         \"additionalProperties\": false\nL63:       },\nL64:       \"minItems\": 4,\nL65:       \"maxItems\": 10\nL66:     }\nL67:   },\nL68:   \"required\": [\nL69:     \"claims\"\nL70:   ],\nL71:   \"additionalProperties\": false\nL72: }",
            "callId": "call_R5LCECqOFmsf1EciVCig27vB"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/public_summary.schema.json",
              "offset": 0,
              "limit": 400
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-public_summary\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"headline\": {\nL7:       \"type\": \"string\",\nL8:       \"minLength\": 20,\nL9:       \"maxLength\": 120\nL10:     },\nL11:     \"plain_language_summary\": {\nL12:       \"type\": \"string\",\nL13:       \"minLength\": 180,\nL14:       \"maxLength\": 1200\nL15:     },\nL16:     \"what_is_new\": {\nL17:       \"type\": \"array\",\nL18:       \"items\": {\nL19:         \"type\": \"string\",\nL20:         \"minLength\": 20\nL21:       },\nL22:       \"minItems\": 3,\nL23:       \"maxItems\": 3\nL24:     },\nL25:     \"why_caution_is_needed\": {\nL26:       \"type\": \"array\",\nL27:       \"items\": {\nL28:         \"type\": \"string\",\nL29:         \"minLength\": 20\nL30:       },\nL31:       \"minItems\": 3,\nL32:       \"maxItems\": 5\nL33:     },\nL34:     \"glossary\": {\nL35:       \"type\": \"array\",\nL36:       \"items\": {\nL37:         \"type\": \"object\",\nL38:         \"properties\": {\nL39:           \"term\": {\nL40:             \"type\": \"string\",\nL41:             \"minLength\": 2\nL42:           },\nL43:           \"definition\": {\nL44:             \"type\": \"string\",\nL45:             \"minLength\": 20,\nL46:             \"maxLength\": 220\nL47:           }\nL48:         },\nL49:         \"required\": [\nL50:           \"term\",\nL51:           \"definition\"\nL52:         ],\nL53:         \"additionalProperties\": false\nL54:       },\nL55:       \"minItems\": 4,\nL56:       \"maxItems\": 8\nL57:     },\nL58:     \"open_questions\": {\nL59:       \"type\": \"array\",\nL60:       \"items\": {\nL61:         \"type\": \"string\",\nL62:         \"minLength\": 20\nL63:       },\nL64:       \"minItems\": 3,\nL65:       \"maxItems\": 6\nL66:     }\nL67:   },\nL68:   \"required\": [\nL69:     \"headline\",\nL70:     \"plain_language_summary\",\nL71:     \"what_is_new\",\nL72:     \"why_caution_is_needed\",\nL73:     \"glossary\",\nL74:     \"open_questions\"\nL75:   ],\nL76:   \"additionalProperties\": false\nL77: }",
            "callId": "call_e67oeZfRWW7YvlUs7WcHFn3d"
          }
        ],
        "usage": {
          "promptTokens": 1219,
          "cachedTokens": 0,
          "responseTokens": 162,
          "thinkingTokens": 52,
          "totalTokens": 1433
        },
        "costUsd": 0.00073275
      },
      {
        "step": 5,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "input/report.md",
              "offset": 24,
              "limit": 40
            },
            "output": "L25: ## Quantitative Findings\nL26: | Metric | Vaccine/Combination Arm | Comparator | Interpretation |\nL27: |---|---:|---:|---|\nL28: | Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |\nL29: | Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |\nL30: | Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |\nL31: | Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |\nL32: | PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable |\nL33: | Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy |\nL34: \nL35: ## Controls and Null/Conditional Results\nL36: - Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\nL37: - ICI-only treatment had limited activity in low-immunogenic baseline settings.\nL38: - Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\nL39: - Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\nL40: \nL41: ## Mechanistic Chain Proposed by Authors\nL42: 1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\nL43: 2. Interferon-associated antigen processing and presentation pathways increase.\nL44: 3. A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\nL45: 4. PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\nL46: 5. Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\nL47: \nL48: ## Caveats and Threats to Validity\nL49: - The human analysis is retrospective and non-randomized; residual confounding is likely.\nL50: - Vaccination timing relative to ICI initiation varied across patients.\nL51: - Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\nL52: - Mouse model effects may not map one-to-one to all human tumors.\nL53: - Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\nL54: \nL55: ## Practical Takeaway\nL56: The study supports a biologically coherent hypothesis that intratumoral mRNA vaccination can prime tumors for stronger ICI responses, but prospective randomized studies are required before clinical protocol changes are justified.",
            "callId": "call_lELPNwSRnGJ1xUzFRYxOrGHV"
          }
        ],
        "usage": {
          "promptTokens": 5417,
          "cachedTokens": 1024,
          "responseTokens": 31,
          "thinkingTokens": 784,
          "totalTokens": 6232
        },
        "costUsd": 0.00275385
      },
      {
        "step": 6,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "list_directory",
            "input": {
              "dir_path": "output",
              "ignore": [
                ".git"
              ],
              "file_filtering_options": {
                "respect_git_ignore": true,
                "respect_gemini_ignore": true
              }
            },
            "output": "claim_audit.json\npublic_summary.json\nquantitative_findings.json\nstudy_overview.json",
            "callId": "call_iXYmfHEBMouYXfdpjuBAdIyM"
          }
        ],
        "usage": {
          "promptTokens": 6097,
          "cachedTokens": 5248,
          "responseTokens": 46,
          "thinkingTokens": 1956,
          "totalTokens": 8099
        },
        "costUsd": 0.00434745
      },
      {
        "step": 7,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/study_overview.json",
              "offset": 0,
              "limit": 400
            },
            "output": "L1: {}",
            "callId": "call_1l4G8zNW4bSd8gyfYuJVWVYb"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "offset": 0,
              "limit": 400
            },
            "output": "L1: {}",
            "callId": "call_4ixe6s5hLAFLWOCmgHNzPsR0"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "offset": 0,
              "limit": 400
            },
            "output": "L1: {}",
            "callId": "call_gU1dcoi3CGr8kN4QU755iXXj"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/public_summary.json",
              "offset": 0,
              "limit": 400
            },
            "output": "L1: {}",
            "callId": "call_sxjOfF9Lv5maXCKBXiTDQ90M"
          }
        ],
        "usage": {
          "promptTokens": 6171,
          "cachedTokens": 6016,
          "responseTokens": 133,
          "thinkingTokens": 93,
          "totalTokens": 6397
        },
        "costUsd": 0.00064115
      },
      {
        "step": 8,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/study_overview.json",
              "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Can intratumoral mRNA vaccination increase tumor immunogenicity and improve response to anti-PD-L1 immune checkpoint blockade in mice and in retrospective human ICI-treated patients?\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-efficacy-cohort\",\n      \"label\": \"Mouse efficacy cohort\",\n      \"sample_size_or_observations\": \"78 mice\",\n      \"description\": \"Preclinical mice with tumor-bearing models receiving the combination therapy arm across pooled repeat experiments.\"\n    },\n    {\n      \"id\": \"mouse-control-cohort\",\n      \"label\": \"Mouse control cohort\",\n      \"sample_size_or_observations\": \"84 mice\",\n      \"description\": \"Matched preclinical controls (vaccine only, ICI only, and vehicle), pooled across repeat mouse experiments.\"\n    },\n    {\n      \"id\": \"human-retrospective-cohort\",\n      \"label\": \"Human retrospective cohort\",\n      \"sample_size_or_observations\": \"130 patients\",\n      \"description\": \"Retrospective cohort of metastatic patients receiving ICI, stratified by prior SARS-CoV-2 mRNA vaccination status.\"\n    },\n    {\n      \"id\": \"human-vaccinated-subgroup\",\n      \"label\": \"Human vaccinated subgroup\",\n      \"sample_size_or_observations\": \"43 patients\",\n      \"description\": \"Retrospective vaccinated subgroup within the human cohort used for survival comparison versus unvaccinated patients.\"\n    },\n    {\n      \"id\": \"human-unvaccinated-subgroup\",\n      \"label\": \"Human unvaccinated subgroup\",\n      \"sample_size_or_observations\": \"87 patients\",\n      \"description\": \"Retrospective unvaccinated comparator subgroup within the same ICI-treated metastatic patient cohort.\"\n    }\n  ],\n  \"major_limitations\": [\n    \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n    \"Vaccination timing relative to ICI initiation varied across patients in the retrospective human cohort.\",\n    \"Tumor-type mix and prior treatment-history heterogeneity limit direct causal interpretation of outcomes.\",\n    \"Mouse model effects may not map one-to-one to all human tumors.\",\n    \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/study_overview.json",
            "callId": "call_ivTsVpRWs69KStakSYKI7EbZ"
          }
        ],
        "usage": {
          "promptTokens": 6358,
          "cachedTokens": 6016,
          "responseTokens": 658,
          "thinkingTokens": 3427,
          "totalTokens": 10443
        },
        "costUsd": 0.008405900000000001
      },
      {
        "step": 9,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3%\",\n      \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination.\",\n      \"evidence_line_refs\": [\"L28\"]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6%\",\n      \"interpretation\": \"Strong expansion of MHC-I-presented landscape.\",\n      \"evidence_line_refs\": [\"L29\"]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value\",\n      \"id_duplicate\": \"Q03\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"N/A\",\n      \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment.\n\",\"evidence_line_refs\": [\"L30\"]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0\",\n      \"interpretation\": \"Marked induction after mRNA vaccination in tumors.\",\n      \"evidence_line_refs\": [\"L31\"]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Checkpoint axis became more targetable.\",\n      \"evidence_line_refs\": [\"L32\"]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Increased immune infiltration with combination therapy.\",\n      \"evidence_line_refs\": [\"L33\"]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n      \"evidence_line_ref\": \"L37\"\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the observed sensitization effect.\",\n      \"evidence_line_ref\": \"L38\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/quantitative_findings.json",
            "callId": "call_Ls19U2k9ycvBAOlFrCEzgdmU"
          }
        ],
        "usage": {
          "promptTokens": 7035,
          "cachedTokens": 6272,
          "responseTokens": 786,
          "thinkingTokens": 0,
          "totalTokens": 7821
        },
        "costUsd": 0.00191955
      },
      {
        "step": 10,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "offset": 0,
              "limit": 400
            },
            "output": "L1: {\nL2:   \"findings\": [\nL3:     {\nL4:       \"id\": \"Q01\",\nL5:       \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\nL6:       \"value\": \"62.3%\",\nL7:       \"comparator_or_baseline\": \"37.3%\",\nL8:       \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination.\",\nL9:       \"evidence_line_refs\": [\"L28\"]\nL10:     },\nL11:     {\nL12:       \"id\": \"Q02\",\nL13:       \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\nL14:       \"value\": \"40.6%\",\nL15:       \"comparator_or_baseline\": \"20.6%\",\nL16:       \"interpretation\": \"Strong expansion of MHC-I-presented landscape.\",\nL17:       \"evidence_line_refs\": [\"L29\"]\nL18:     },\nL19:     {\nL20:       \"id\": \"Q03\",\nL21:       \"metric\": \"Retrospective human survival comparison p-value\",\nL22:       \"id_duplicate\": \"Q03\",\nL23:       \"value\": \"p=0.01\",\nL24:       \"comparator_or_baseline\": \"N/A\",\nL25:       \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment.\nL26: \",\"evidence_line_refs\": [\"L30\"]\nL27:     },\nL28:     {\nL29:       \"id\": \"Q04\",\nL30:       \"metric\": \"Type I interferon response score (normalized units)\",\nL31:       \"value\": \"3.1\",\nL32:       \"comparator_or_baseline\": \"1.0\",\nL33:       \"interpretation\": \"Marked induction after mRNA vaccination in tumors.\",\nL34:       \"evidence_line_refs\": [\"L31\"]\nL35:     },\nL36:     {\nL37:       \"id\": \"Q05\",\nL38:       \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\nL39:       \"value\": \"2.4x\",\nL40:       \"comparator_or_baseline\": \"1.0x\",\nL41:       \"interpretation\": \"Checkpoint axis became more targetable.\",\nL42:       \"evidence_line_refs\": [\"L32\"]\nL43:     },\nL44:     {\nL45:       \"id\": \"Q06\",\nL46:       \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\nL47:       \"value\": \"1.8x\",\nL48:       \"comparator_or_baseline\": \"1.0x\",\nL49:       \"interpretation\": \"Increased immune infiltration with combination therapy.\",\nL50:       \"evidence_line_refs\": [\"L33\"]\nL51:     }\nL52:   ],\nL53:   \"controls_or_null_results\": [\nL54:     {\nL55:       \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\nL56:       \"evidence_line_ref\": \"L36\"\nL57:     },\nL58:     {\nL59:       \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\nL60:       \"evidence_line_ref\": \"L37\"\nL61:     },\nL62:     {\nL63:       \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the observed sensitization effect.\",\nL64:       \"evidence_line_ref\": \"L38\"\nL65:     },\nL66:     {\nL67:       \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\nL68:       \"evidence_line_ref\": \"L39\"\nL69:     }\nL70:   ]\nL71: }",
            "callId": "call_sGijWtC9oazpWfvbPylxNXB2"
          }
        ],
        "usage": {
          "promptTokens": 7843,
          "cachedTokens": 6912,
          "responseTokens": 35,
          "thinkingTokens": 114,
          "totalTokens": 7992
        },
        "costUsd": 0.00070355
      },
      {
        "step": 11,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3%\",\n      \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination.\",\n      \"evidence_line_refs\": [\"L28\"]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6%\",\n      \"interpretation\": \"Strong expansion of MHC-I-presented landscape.\",\n      \"evidence_line_refs\": [\"L29\"]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"N/A\",\n      \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment.\",\n      \"evidence_line_refs\": [\"L30\"]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0\",\n      \"interpretation\": \"Marked induction after mRNA vaccination in tumors.\",\n      \"evidence_line_refs\": [\"L31\"]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Checkpoint axis became more targetable.\",\n      \"evidence_line_refs\": [\"L32\"]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Increased immune infiltration with combination therapy.\",\n      \"evidence_line_refs\": [\"L33\"]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n      \"evidence_line_ref\": \"L37\"\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the observed sensitization effect.\",\n      \"evidence_line_ref\": \"L38\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/quantitative_findings.json",
            "callId": "call_d2XIpKnHEQHXbTOYJmlIf2Cq"
          }
        ],
        "usage": {
          "promptTokens": 8739,
          "cachedTokens": 7680,
          "responseTokens": 781,
          "thinkingTokens": 1718,
          "totalTokens": 11238
        },
        "costUsd": 0.0054547499999999995
      },
      {
        "step": 12,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/study_overview.json",
              "offset": 0,
              "limit": 400
            },
            "output": "L1: {\nL2:   \"paper\": {\nL3:     \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\nL4:     \"doi\": \"10.1038/s41586-025-09006-8\",\nL5:     \"publication_year\": 2025,\nL6:     \"domain\": \"oncology-immunology\",\nL7:     \"study_type\": \"preclinical+retrospective\"\nL8:   },\nL9:   \"core_question\": \"Can intratumoral mRNA vaccination increase tumor immunogenicity and improve response to anti-PD-L1 immune checkpoint blockade in mice and in retrospective human ICI-treated patients?\",\nL10:   \"datasets_or_cohorts\": [\nL11:     {\nL12:       \"id\": \"mouse-efficacy-cohort\",\nL13:       \"label\": \"Mouse efficacy cohort\",\nL14:       \"sample_size_or_observations\": \"78 mice\",\nL15:       \"description\": \"Preclinical mice with tumor-bearing models receiving the combination therapy arm across pooled repeat experiments.\"\nL16:     },\nL17:     {\nL18:       \"id\": \"mouse-control-cohort\",\nL19:       \"label\": \"Mouse control cohort\",\nL20:       \"sample_size_or_observations\": \"84 mice\",\nL21:       \"description\": \"Matched preclinical controls (vaccine only, ICI only, and vehicle), pooled across repeat mouse experiments.\"\nL22:     },\nL23:     {\nL24:       \"id\": \"human-retrospective-cohort\",\nL25:       \"label\": \"Human retrospective cohort\",\nL26:       \"sample_size_or_observations\": \"130 patients\",\nL27:       \"description\": \"Retrospective cohort of metastatic patients receiving ICI, stratified by prior SARS-CoV-2 mRNA vaccination status.\"\nL28:     },\nL29:     {\nL30:       \"id\": \"human-vaccinated-subgroup\",\nL31:       \"label\": \"Human vaccinated subgroup\",\nL32:       \"sample_size_or_observations\": \"43 patients\",\nL33:       \"description\": \"Retrospective vaccinated subgroup within the human cohort used for survival comparison versus unvaccinated patients.\"\nL34:     },\nL35:     {\nL36:       \"id\": \"human-unvaccinated-subgroup\",\nL37:       \"label\": \"Human unvaccinated subgroup\",\nL38:       \"sample_size_or_observations\": \"87 patients\",\nL39:       \"description\": \"Retrospective unvaccinated comparator subgroup within the same ICI-treated metastatic patient cohort.\"\nL40:     }\nL41:   ],\nL42:   \"major_limitations\": [\nL43:     \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\nL44:     \"Vaccination timing relative to ICI initiation varied across patients in the retrospective human cohort.\",\nL45:     \"Tumor-type mix and prior treatment-history heterogeneity limit direct causal interpretation of outcomes.\",\nL46:     \"Mouse model effects may not map one-to-one to all human tumors.\",\nL47:     \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\nL48:   ]\nL49: }",
            "callId": "call_EPvKC5ojfCHl1y8mcZXlca0f"
          }
        ],
        "usage": {
          "promptTokens": 9540,
          "cachedTokens": 8576,
          "responseTokens": 34,
          "thinkingTokens": 1493,
          "totalTokens": 11067
        },
        "costUsd": 0.0035093999999999998
      },
      {
        "step": 13,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination can increase tumor immunogenicity and improve response to anti-PD-L1 therapy by increasing MHC-I antigen presentation pathways.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n          \"line_ref\": \"L42\"\n        },\n        {\n          \"quote\": \"A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\",\n          \"line_ref\": \"L44\"\n        }\n      ],\n      \"caveat\": \"Although mechanistic chain is consistent, effects are strongest in certain models and may not generalize to all tumor types.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"mRNA vaccination induces a stronger type I interferon response in tumors than comparator conditions, consistent with innate immune activation within the tumor microenvironment.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors\",\n          \"line_ref\": \"L31\"\n        },\n        {\n          \"quote\": \"Fraction of tumor proteins represented in immunopeptidome\\n62.3%\\n37.3%\",\n          \"line_ref\": \"L28\"\n        }\n      ],\n      \"caveat\": \"The quantitative measures are summarized in report tables, and full experimental context for each value is not provided in detail.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"Blocking type I interferon signaling with anti-IFNAR1 removes the sensitization benefit, implicating interferon dependence of the response.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\n\",\n          \"line_ref\": \"L39\"\n        },\n        {\n          \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\n\",\n          \"line_ref\": \"L46\"\n        }\n      ],\n      \"caveat\": \"This mechanistic inference is based on pooled preclinical controls and does not yet establish causal proof in patients.\" \n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"The human retrospective cohort analysis suggests vaccinated patients had improved survival under ICI relative to unvaccinated patients.\n\",\n      \"strength\": \"tentative\",\n      \"evidence\": [\n        {\n          \"quote\": \"Retrospective human survival comparison p-value | 0.01\",\n          \"line_ref\": \"L30\"\n        },\n        {\n          \"quote\": \"human analysis is retrospective and non-randomized; residual confounding is likely.\",\n          \"line_ref\": \"L49\"\n        }\n      ],\n      \"caveat\": \"Retrospective non-randomized design with variable vaccination timing and treatment-history heterogeneity limits causal interpretation of survival advantage.\"\n    }\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/claim_audit.json",
            "callId": "call_gsmoN4B6YwpHeNB5SpB1ml7k"
          }
        ],
        "usage": {
          "promptTokens": 10286,
          "cachedTokens": 9344,
          "responseTokens": 803,
          "thinkingTokens": 0,
          "totalTokens": 11089
        },
        "costUsd": 0.0020751
      },
      {
        "step": 14,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "offset": 0,
              "limit": 500
            },
            "output": "L1: {\nL2:   \"claims\": [\nL3:     {\nL4:       \"claim_id\": \"C01\",\nL5:       \"claim\": \"Intratumoral mRNA vaccination can increase tumor immunogenicity and improve response to anti-PD-L1 therapy by increasing MHC-I antigen presentation pathways.\",\nL6:       \"strength\": \"strong\",\nL7:       \"evidence\": [\nL8:         {\nL9:           \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\nL10:           \"line_ref\": \"L42\"\nL11:         },\nL12:         {\nL13:           \"quote\": \"A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\",\nL14:           \"line_ref\": \"L44\"\nL15:         }\nL16:       ],\nL17:       \"caveat\": \"Although mechanistic chain is consistent, effects are strongest in certain models and may not generalize to all tumor types.\"\nL18:     },\nL19:     {\nL20:       \"claim_id\": \"C02\",\nL21:       \"claim\": \"mRNA vaccination induces a stronger type I interferon response in tumors than comparator conditions, consistent with innate immune activation within the tumor microenvironment.\",\nL22:       \"strength\": \"strong\",\nL23:       \"evidence\": [\nL24:         {\nL25:           \"quote\": \"Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors\",\nL26:           \"line_ref\": \"L31\"\nL27:         },\nL28:         {\nL29:           \"quote\": \"Fraction of tumor proteins represented in immunopeptidome\\n62.3%\\n37.3%\",\nL30:           \"line_ref\": \"L28\"\nL31:         }\nL32:       ],\nL33:       \"caveat\": \"The quantitative measures are summarized in report tables, and full experimental context for each value is not provided in detail.\"\nL34:     },\nL35:     {\nL36:       \"claim_id\": \"C03\",\nL37:       \"claim\": \"Blocking type I interferon signaling with anti-IFNAR1 removes the sensitization benefit, implicating interferon dependence of the response.\",\nL38:       \"strength\": \"strong\",\nL39:       \"evidence\": [\nL40:         {\nL41:           \"quote\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\nL42: \",\nL43:           \"line_ref\": \"L39\"\nL44:         },\nL45:         {\nL46:           \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\nL47: \",\nL48:           \"line_ref\": \"L46\"\nL49:         }\nL50:       ],\nL51:       \"caveat\": \"This mechanistic inference is based on pooled preclinical controls and does not yet establish causal proof in patients.\" \nL52:     },\nL53:     {\nL54:       \"claim_id\": \"C04\",\nL55:       \"claim\": \"The human retrospective cohort analysis suggests vaccinated patients had improved survival under ICI relative to unvaccinated patients.\nL56: \",\nL57:       \"strength\": \"tentative\",\nL58:       \"evidence\": [\nL59:         {\nL60:           \"quote\": \"Retrospective human survival comparison p-value | 0.01\",\nL61:           \"line_ref\": \"L30\"\nL62:         },\nL63:         {\nL64:           \"quote\": \"human analysis is retrospective and non-randomized; residual confounding is likely.\",\nL65:           \"line_ref\": \"L49\"\nL66:         }\nL67:       ],\nL68:       \"caveat\": \"Retrospective non-randomized design with variable vaccination timing and treatment-history heterogeneity limits causal interpretation of survival advantage.\"\nL69:     }\nL70:   ]\nL71: }",
            "callId": "call_732CSJngO80AbWLAIw0Oqbyr"
          }
        ],
        "usage": {
          "promptTokens": 11110,
          "cachedTokens": 10112,
          "responseTokens": 32,
          "thinkingTokens": 0,
          "totalTokens": 11142
        },
        "costUsd": 0.0005663
      },
      {
        "step": 15,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/public_summary.json",
              "offset": 0,
              "limit": 500
            },
            "output": "L1: {}",
            "callId": "call_H7PKVWaS2FBqs4gPGRIQhKDc"
          }
        ],
        "usage": {
          "promptTokens": 12036,
          "cachedTokens": 11008,
          "responseTokens": 32,
          "thinkingTokens": 1093,
          "totalTokens": 13161
        },
        "costUsd": 0.0027822
      },
      {
        "step": 16,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/public_summary.json",
              "content": "{\n  \"headline\": \"mRNA vaccines in tumors may boost immunity and improve checkpoint therapy responses.\",\n  \"plain_language_summary\": \"This study shows that treating tumors directly with mRNA vaccines can make them more visible to the immune system and helps some mouse tumors respond better when combined with anti-PD-L1 therapy. In the mouse work, intratumoral vaccination increased tumor antigen display, increased markers linked to immune activity, and also raised PD-L1 levels in tumors. For patients who already received SARS-CoV-2 mRNA vaccines, survival appeared better when they were treated with checkpoint inhibitors, and in a retrospective review of 130 people, 43 had been vaccinated and 87 had not. Human findings suggest potential benefit but are limited because patients were not randomized, treatment histories differed, and vaccination timing was not uniform. This study supports a biologically coherent hypothesis and supports further research, but does not yet justify changing treatment protocols.\n\",\n  \"what_is_new\": [\n    \"The study combined preclinical mouse experiments with retrospective human data, linking laboratory mechanisms to clinical outcomes in a single translational framework.\",\n    \"It includes mechanistic controls suggesting type I interferon signaling is necessary for the sensitization effect, including loss of benefit with anti-IFNAR1 blockade.\",\n    \"The work reports quantitative changes across antigen presentation, interferon activation, PD-L1 expression, and T-cell infiltration with a directionally consistent pattern.\n\",\n    \"The study proposes that intratumoral mRNA vaccination can be used as a tumor-sensitizing strategy and not merely as a systemic vaccine platform.\",\n    \"\"\"\n\"\"\n  ],\n  publicSummaryList: \"true\",\n  \"why_caution_is_needed\": [\n    \"The human analysis is retrospective and non-randomized, so better survival could reflect confounding factors rather than causicality.\",\n    \"Vaccination timing relative to ICI initiation varied, reducing certainty that timing alone does not drive differences.\",\n    \"Tumor-type mix and treatment-history heterogeneity in patients limit generalization to a single cancer context.\",\n    \"Mouse models used in the efficacy experiments may not perfectly mimic human tumor biology.\",\n    \"Some mechanistic endpoints were strongest only in certain model systems and were not uniformly seen across all settings.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"mRNA vaccine\",\n      \"definition\": \"A therapy that teaches cells to make a protein from messenger RNA, used here by injection into tumors to stimulate local immune sensing.\"\n    },\n    {\n      \"term\": \"PD-L1\",\n      \"definition\": \"A protein on tumor and immune cells that can suppress T-cell activity; anti-PD-L1 therapy blocks this suppression.\" \n    },\n    \"\",\n    {\n      \"term\": \"Type I interferon\",\n      \"term2\": \"Interferon\",\n      \"definition\": \"Immune signaling molecules that help turn on antiviral and antitumor responses in nearby immune cells and tissues.\"\n    },\n    {\n      \"term\": \"Immunopeptidome\",\n      \"definition\": \"The set of peptides presented on a cell surface by MHC molecules and available for immune recognition.\n\"\n    },\n    {\n      \"term\": \"Retrospective cohort\",\n      \"definition\": \"A study that looks back at existing patients and outcomes instead of assigning treatments prospectively in a randomized trial.\"\n    }\n  ],\n  \"open_questions\": [\n    \"What is the safest and most effective clinical schedule for intratumoral mRNA vaccination relative to starting anti-PD-L1 therapy?\",\n    \"Can similar sensitization be demonstrated in specific human cancers beyond the mixed retrospective cohort?\",\n    \"Which patients can be identified prospectively as likely responders based on interferon or antigen-presentation signatures?\n\",\n    \"How durable and durable are the response benefits beyond the initial observation window reported?\",\n    \"Could combining mRNA vaccination with other checkpoint inhibitors or modalities further improve outcomes?\"\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/public_summary.json",
            "callId": "call_oT4yvcy067rxpD09UxLx1bZo"
          }
        ],
        "usage": {
          "promptTokens": 12081,
          "cachedTokens": 11904,
          "responseTokens": 915,
          "thinkingTokens": 0,
          "totalTokens": 12996
        },
        "costUsd": 0.00217185
      },
      {
        "step": 17,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "input/report.md",
              "offset": 0,
              "limit": 100
            },
            "output": "L1: # Structured Paper Report: Tumor Sensitization by mRNA Vaccination\nL2: \nL3: ## Citation\nL4: - Title: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\nL5: - Journal: Nature\nL6: - Year: 2025\nL7: - DOI: 10.1038/s41586-025-09006-8\nL8: - Source URL: https://www.nature.com/articles/s41586-025-09006-8\nL9: \nL10: ## One-Paragraph Context\nL11: Immune checkpoint inhibitors (ICIs) can produce durable responses in some cancers, but many tumors remain non-responsive due to weak antigen presentation or poor immune priming. The paper investigates whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy.\nL12: \nL13: ## Study Design Snapshot\nL14: - Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\nL15: - Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\nL16: - Mechanistic probes: immunopeptidomics, transcriptomics, and perturbation controls (including IFNAR1 blockade and non-mRNA particle controls).\nL17: \nL18: ## Cohorts and Scenarios\nL19: 1. Mouse efficacy cohort (combination therapy): 78 tumor-bearing mice pooled across repeat experiments.\nL20: 2. Mouse control cohort (vaccine only, ICI only, and vehicle): 84 tumor-bearing mice pooled across matched controls.\nL21: 3. Human retrospective metastatic cohort: 130 patients total.\nL22: 4. Human vaccinated subgroup: 43 patients.\nL23: 5. Human unvaccinated subgroup: 87 patients.\nL24: \nL25: ## Quantitative Findings\nL26: | Metric | Vaccine/Combination Arm | Comparator | Interpretation |\nL27: |---|---:|---:|---|\nL28: | Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |\nL29: | Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |\nL30: | Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |\nL31: | Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |\nL32: | PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable |\nL33: | Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy |\nL34: \nL35: ## Controls and Null/Conditional Results\nL36: - Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\nL37: - ICI-only treatment had limited activity in low-immunogenic baseline settings.\nL38: - Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\nL39: - Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\nL40: \nL41: ## Mechanistic Chain Proposed by Authors\nL42: 1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\nL43: 2. Interferon-associated antigen processing and presentation pathways increase.\nL44: 3. A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\nL45: 4. PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\nL46: 5. Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\nL47: \nL48: ## Caveats and Threats to Validity\nL49: - The human analysis is retrospective and non-randomized; residual confounding is likely.\nL50: - Vaccination timing relative to ICI initiation varied across patients.\nL51: - Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\nL52: - Mouse model effects may not map one-to-one to all human tumors.\nL53: - Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\nL54: \nL55: ## Practical Takeaway\nL56: The study supports a biologically coherent hypothesis that intratumoral mRNA vaccination can prime tumors for stronger ICI responses, but prospective randomized studies are required before clinical protocol changes are justified.",
            "callId": "call_13chW9Q4yoKwBQBvhjbt4NWy"
          }
        ],
        "usage": {
          "promptTokens": 13015,
          "cachedTokens": 11904,
          "responseTokens": 31,
          "thinkingTokens": 1073,
          "totalTokens": 14119
        },
        "costUsd": 0.00278335
      },
      {
        "step": 18,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "offset": 0,
              "limit": 500
            },
            "output": "L1: {\nL2:   \"findings\": [\nL3:     {\nL4:       \"id\": \"Q01\",\nL5:       \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\nL6:       \"value\": \"62.3%\",\nL7:       \"comparator_or_baseline\": \"37.3%\",\nL8:       \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination.\",\nL9:       \"evidence_line_refs\": [\"L28\"]\nL10:     },\nL11:     {\nL12:       \"id\": \"Q02\",\nL13:       \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\nL14:       \"value\": \"40.6%\",\nL15:       \"comparator_or_baseline\": \"20.6%\",\nL16:       \"interpretation\": \"Strong expansion of MHC-I-presented landscape.\",\nL17:       \"evidence_line_refs\": [\"L29\"]\nL18:     },\nL19:     {\nL20:       \"id\": \"Q03\",\nL21:       \"metric\": \"Retrospective human survival comparison p-value\",\nL22:       \"value\": \"p=0.01\",\nL23:       \"comparator_or_baseline\": \"N/A\",\nL24:       \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment.\",\nL25:       \"evidence_line_refs\": [\"L30\"]\nL26:     },\nL27:     {\nL28:       \"id\": \"Q04\",\nL29:       \"metric\": \"Type I interferon response score (normalized units)\",\nL30:       \"value\": \"3.1\",\nL31:       \"comparator_or_baseline\": \"1.0\",\nL32:       \"interpretation\": \"Marked induction after mRNA vaccination in tumors.\",\nL33:       \"evidence_line_refs\": [\"L31\"]\nL34:     },\nL35:     {\nL36:       \"id\": \"Q05\",\nL37:       \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\nL38:       \"value\": \"2.4x\",\nL39:       \"comparator_or_baseline\": \"1.0x\",\nL40:       \"interpretation\": \"Checkpoint axis became more targetable.\",\nL41:       \"evidence_line_refs\": [\"L32\"]\nL42:     },\nL43:     {\nL44:       \"id\": \"Q06\",\nL45:       \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\nL46:       \"value\": \"1.8x\",\nL47:       \"comparator_or_baseline\": \"1.0x\",\nL48:       \"interpretation\": \"Increased immune infiltration with combination therapy.\",\nL49:       \"evidence_line_refs\": [\"L33\"]\nL50:     }\nL51:   ],\nL52:   \"controls_or_null_results\": [\nL53:     {\nL54:       \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\nL55:       \"evidence_line_ref\": \"L36\"\nL56:     },\nL57:     {\nL58:       \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\nL59:       \"evidence_line_ref\": \"L37\"\nL60:     },\nL61:     {\nL62:       \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the observed sensitization effect.\",\nL63:       \"evidence_line_ref\": \"L38\"\nL64:     },\nL65:     {\nL66:       \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\nL67:       \"evidence_line_ref\": \"L39\"\nL68:     }\nL69:   ]\nL70: }",
            "callId": "call_asvQJbIM7mL0ZiyOa1To6kPu"
          }
        ],
        "usage": {
          "promptTokens": 14119,
          "cachedTokens": 12928,
          "responseTokens": 35,
          "thinkingTokens": 1391,
          "totalTokens": 15545
        },
        "costUsd": 0.00347295
      },
      {
        "step": 19,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination is proposed to increase tumor immunogenicity and improve anti-PD-L1 responses by expanding antigen presentation on MHC-I.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n          \"line_ref\": \"L42\"\n        },\n        {\n          \"quote\": \"A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\",\n          \"line_ref\": \"L44\"\n        }\n      ],\n      \"caveat\": \"The report notes that some mechanistic readouts were strongest in specific model systems, so effects may not be uniform across tumors.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"mRNA vaccination induces higher type I interferon activity in tumors than comparator conditions in the mouse experiments.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors\",\n          \"line_ref\": \"L31\"\n        },\n        {\n          \"quote\": \"Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination\",\n          \"line_ref\": \"L28\"\n        }\n      ],\n      \"caveat\": \"The table summarizes these values, and the report does not provide additional design details for each numerical comparison in this extract.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"Type I interferon signaling is necessary for the sensitization benefit in preclinical settings, because anti-IFNAR1 blockade abolished the benefit.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n          \"line_ref\": \"L39\"\n        },\n        {\n          \"quote\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n          \"line_ref\": \"L38\"\n        }\n      ],\n      \"caveat\": \"This is a mechanistic inference from preclinical perturbation controls and cannot by itself prove causality in patients.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"In the retrospective human cohort, prior SARS-CoV-2 mRNA vaccination was associated with improved survival under ICI treatment compared with no prior vaccination.\",\n      \"strength\": \"tentative\",\n      \"evidence\": [\n        {\n          \"quote\": \"Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment\",\n          \"line_ref\": \"L30\"\n        },\n        {\n          \"quote\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n          \"line_ref\": \"L49\"\n        }\n      ],\n      \"caveat\": \"This analysis is retrospective with heterogeneous tumor types and variable vaccination timing, so unmeasured confounding may influence outcomes.\"\n    }\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/claim_audit.json",
            "callId": "call_hM4CVUSe03OL5uU3DE7Q56jJ"
          }
        ],
        "usage": {
          "promptTokens": 15004,
          "cachedTokens": 13952,
          "responseTokens": 836,
          "thinkingTokens": 1911,
          "totalTokens": 17751
        },
        "costUsd": 0.0061058
      },
      {
        "step": 20,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "offset": 0,
              "limit": 500
            },
            "output": "L1: {\nL2:   \"claims\": [\nL3:     {\nL4:       \"claim_id\": \"C01\",\nL5:       \"claim\": \"Intratumoral mRNA vaccination is proposed to increase tumor immunogenicity and improve anti-PD-L1 responses by expanding antigen presentation on MHC-I.\",\nL6:       \"strength\": \"moderate\",\nL7:       \"evidence\": [\nL8:         {\nL9:           \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\nL10:           \"line_ref\": \"L42\"\nL11:         },\nL12:         {\nL13:           \"quote\": \"A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\",\nL14:           \"line_ref\": \"L44\"\nL15:         }\nL16:       ],\nL17:       \"caveat\": \"The report notes that some mechanistic readouts were strongest in specific model systems, so effects may not be uniform across tumors.\"\nL18:     },\nL19:     {\nL20:       \"claim_id\": \"C02\",\nL21:       \"claim\": \"mRNA vaccination induces higher type I interferon activity in tumors than comparator conditions in the mouse experiments.\",\nL22:       \"strength\": \"strong\",\nL23:       \"evidence\": [\nL24:         {\nL25:           \"quote\": \"Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors\",\nL26:           \"line_ref\": \"L31\"\nL27:         },\nL28:         {\nL29:           \"quote\": \"Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination\",\nL30:           \"line_ref\": \"L28\"\nL31:         }\nL32:       ],\nL33:       \"caveat\": \"The table summarizes these values, and the report does not provide additional design details for each numerical comparison in this extract.\"\nL34:     },\nL35:     {\nL36:       \"claim_id\": \"C03\",\nL37:       \"claim\": \"Type I interferon signaling is necessary for the sensitization benefit in preclinical settings, because anti-IFNAR1 blockade abolished the benefit.\",\nL38:       \"strength\": \"strong\",\nL39:       \"evidence\": [\nL40:         {\nL41:           \"quote\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\nL42:           \"line_ref\": \"L39\"\nL43:         },\nL44:         {\nL45:           \"quote\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\nL46:           \"line_ref\": \"L38\"\nL47:         }\nL48:       ],\nL49:       \"caveat\": \"This is a mechanistic inference from preclinical perturbation controls and cannot by itself prove causality in patients.\"\nL50:     },\nL51:     {\nL52:       \"claim_id\": \"C04\",\nL53:       \"claim\": \"In the retrospective human cohort, prior SARS-CoV-2 mRNA vaccination was associated with improved survival under ICI treatment compared with no prior vaccination.\",\nL54:       \"strength\": \"tentative\",\nL55:       \"evidence\": [\nL56:         {\nL57:           \"quote\": \"Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment\",\nL58:           \"line_ref\": \"L30\"\nL59:         },\nL60:         {\nL61:           \"quote\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\nL62:           \"line_ref\": \"L49\"\nL63:         }\nL64:       ],\nL65:       \"caveat\": \"This analysis is retrospective with heterogeneous tumor types and variable vaccination timing, so unmeasured confounding may influence outcomes.\"\nL66:     }\nL67:   ]\nL68: }",
            "callId": "call_j2TMDLLsl3jRNAWS8JujpMXB"
          }
        ],
        "usage": {
          "promptTokens": 15859,
          "cachedTokens": 14848,
          "responseTokens": 32,
          "thinkingTokens": 0,
          "totalTokens": 15891
        },
        "costUsd": 0.0006879500000000001
      },
      {
        "step": 21,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/public_summary.json",
              "content": "{\n  \"headline\": \"Tumor mRNA vaccination may sensitize cancers to checkpoint blockade\",\n  \"plain_language_summary\": \"This study reports that giving an mRNA vaccine directly into tumors increased tumor immune visibility and signaling in preclinical mouse models, especially when paired with anti-PD-L1 therapy. Across repeated murine experiments, combination treatment and related measurements showed stronger antigen presentation on MHC-I, higher type I interferon signatures, increased PD-L1 expression, and greater intratumoral CD8+ T-cell density. In a retrospective cohort of 130 metastatic patients treated with immune checkpoint inhibitors, 43 had prior SARS-CoV-2 mRNA vaccination and 87 did not; the vaccinated subgroup had a reported survival p-value of 0.01 and appeared to fare better. The authors conclude these findings support a biologically coherent, tumor-sensitizing strategy while cautioning that retrospective non-randomized data limit causal interpretation and that prospective randomized studies are still needed before changing treatment protocols.\",\n  \"what_is_new\": [\n    \"The work combines preclinical mechanistic studies with a human retrospective cohort to link mRNA-driven tumor sensitization to both biology and patient outcomes.\",\n    \"It identifies type I interferon signaling as a key required pathway, with anti-IFNAR1 blockade reported to eliminate the sensitization effect.\",\n    \"The study reports coordinated quantitative shifts in multiple immune-readout domains, including antigen presentation, PD-L1 pathway activity, and CD8+ T-cell infiltration.\",\n    \"It proposes intratumoral mRNA vaccination as a local sensitizing step for checkpoint therapy rather than only a systemic vaccine platform.\",\n    \"It provides a retrospective human association where vaccinated and unvaccinated ICI-treated patients are compared within a metastatic cohort.\",\n    \"It includes control conditions such as non-immunogenic models, ICI-only and vaccine-only arms, and non-mRNA particle controls to benchmark specificity.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human evidence is retrospective and non-randomized, so causal inference is limited by potential confounding.\",\n    \"Vaccination timing relative to ICI start varied across patients, creating heterogeneity in exposure context.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"mRNA vaccine\",\n      \"definition\": \"A delivery of messenger RNA that instructs local cells to produce a protein and trigger immune activation inside the tumor environment.\"\n    },\n    {\n      \"term\": \"Anti-PD-L1\",\n      \"definition\": \"An immune checkpoint therapy that blocks PD-L1 signaling, reducing suppression of T-cell attack on tumors.\"\n    },\n    {\n      \"term\": \"Retrospective cohort\",\n      \"definition\": \"A study design that analyzes existing patient records after treatment has already occurred, rather than randomly assigning therapies in advance.\"\n    },\n    {\n      \"term\": \"Immunopeptidome\",\n      \"definition\": \"The set of peptide fragments displayed on cell surfaces that can be recognized by immune cells via MHC molecules.\"\n    },\n    {\n      \"term\": \"Type I interferon\",\n      \"definition\": \"A family of immune cytokines that trigger antiviral and anti-tumor signaling pathways and help shape antigen presentation.\"\n    },\n    {\n      \"term\": \"MHC-I\",\n      \"definition\": \"A molecule family on cells that presents internal protein-derived peptides to CD8+ T cells for immune surveillance.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Which prospective trial design will best test whether these preclinical mechanistic findings translate to specific human cancers?\",\n    \"Can efficacy be reproduced in a randomized setting with standardized vaccination timing relative to ICI treatment?\",\n    \"What biomarkers best identify patients most likely to benefit from intratumoral mRNA vaccination sensitization?\",\n    \"How durable are responses and what are potential resistance mechanisms after initial sensitization occurs?\"\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/public_summary.json",
            "callId": "call_RcK5pnKOllzvE49v4H3a6jik"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/public_summary.json",
              "content": "{\n  \"headline\": \"mRNA vaccines in tumors can increase sensitivity to immune checkpoint blockade in mice, with suggestive patient survival signals.\",\n  \"plain_language_summary\": \"This study looked at how injecting an mRNA vaccine directly into tumors affects response to anti-PD-L1 therapy. In mice, intratumoral mRNA delivery increased immune-related tumor measures such as antigen display, MHC-I presentation, type I interferon response, PD-L1 expression, and CD8+ T-cell density, while control conditions showed limited benefit, supporting a mechanistic sensitization idea. In patients, a retrospective analysis of 130 metastatic patients receiving checkpoint inhibitors (43 vaccinated, 87 unvaccinated) reported a survival p-value of p=0.01 favoring the vaccinated group. The authors present this as biologically coherent and translationally relevant, but because the human evidence is non-randomized and mixed across tumor types/treatments, they emphasize the need for prospective randomized confirmation before any protocol change.\",\n  \"what_is_new\": [\n    \"The study combines preclinical and human retrospective evidence to connect mechanistic sensitization biology with clinical association signals.\",\n    \"It reports a possible key role for type I interferon signaling, with anti-IFNAR1 blockade removing the sensitization benefit.\",\n    \"Quantitative readouts across multiple immune axes consistently move in a pro-immunity direction in treated tumors.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human cohort was retrospective and non-randomized, so better outcomes could reflect confounding.\",\n    \"Vaccination timing relative to ICI initiation varied across patients.\",\n    \"Tumor-type mix and treatment-history heterogeneity complicate direct causal interpretation.\",\n    \"Mouse-model findings may not generalize to all human cancers.\",\n    \"Some mechanistic readouts were strongest in specific model systems and not uniform across settings.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"mRNA vaccine\",\n      \"definition\": \"A vaccine approach where mRNA is delivered to cells so they produce antigen and stimulate immune signaling locally.\"\n    },\n    {\n      \"term\": \"PD-L1\",\n      \"definition\": \"A checkpoint protein that suppresses T-cell killing; blocking it with therapy can restore immune attack on tumors.\"\n    },\n    {\n      \"term\": \"Retrospective study\",\n      \"definition\": \"Analysis of previously collected patient data without random assignment of treatment at the time of care.\"\n    },\n    {\n      \"term\": \"CD8+ T-cell\",\n      \"definition\": \"A cytotoxic immune cell subtype that can recognize and kill tumor cells when adequately activated.\"\n      \n    },\n    {\n      \"term\": \"Type I interferon\",\n      \"definition\": \"A family of cytokines that promote antiviral-like immune programs, including antigen processing and presentation.\"\n    },\n    {\n      \"term\": \"Immunopeptidome\",\n      \"definition\": \"The pool of peptides shown on cell surfaces by MHC molecules for immune recognition.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Which cancer types will show the strongest clinical benefit in prospective testing?\",\n    \"What is the optimal schedule of intratumoral mRNA administration relative to ICI start and dosing?\",\n    \"Can biomarker profiles predict which patients can benefit most from this sensitization strategy?\",\n    \"What are the durability and long-term safety implications of intratumoral mRNA vaccination combined with checkpoint therapy?\"\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/public_summary.json",
            "callId": "call_2q1iwtOORNZ0epM3Ht547kDq"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/public_summary.json",
              "content": "{\n  \"headline\": \"Tumor-local mRNA vaccination can sensitize cancers to anti-PD-L1 therapy, with supportive mouse data and retrospective patient signals.\",\n  \"plain_language_summary\": \"This study examined whether mRNA vaccines injected into tumors could make cancers more visible to the immune system and improve response to anti-PD-L1 checkpoint therapy. In multiple mouse models, intratumoral mRNA vaccination improved immune-related measurements in combination with ICI: increased antigen display, MHC-I peptide presentation, type I interferon response, PD-L1 fold-change, and higher CD8+ T-cell density. Control experiments also showed specificity, including limited benefit in vaccine-only or ICI-only settings in some models and loss of effect when type I interferon signaling was blocked. In humans, a retrospective cohort of 130 metastatic patients receiving ICI (43 vaccinated, 87 unvaccinated) reported a p-value of 0.01 for better survival in the vaccinated group. The report stresses that these associations are observational, and confirms that prospective randomized trials are needed before changing clinical protocols.\",\n  \"what_is_new\": [\n    \"The study links mechanistic preclinical findings to human survival associations in the same overall translational program.\",\n    \"It identifies type I interferon signaling as a requirement for the effect through anti-IFNAR1 blocking evidence.\",\n    \"The work reports a suite of quantitative outcomes across antigen presentation, interferon activation, checkpoint signaling, and T-cell infiltration.\",\n    \"It explicitly tests non-mRNA particle controls and ICI-only/vaccine-only arms as part of the sensitization interpretation.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human component is retrospective and non-randomized, so residual confounding is a concern.\",\n    \"Vaccination timing relative to ICI initiation varied across patients, creating interpretation uncertainty.\",\n    \"The patient cohort is heterogeneous in tumor type and treatment history, limiting direct causal conclusions.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"mRNA vaccine\",\n      \"definition\": \"A treatment using messenger RNA to program local cells to produce antigen and ignite local immune signaling in a tumor.\"\n    },\n    {\n      \"term\": \"PD-L1\",\n      \"definition\": \"A checkpoint protein that inhibits T-cell function; anti-PD-L1 therapy blocks this brake to enable tumor cell killing.\"\n    },\n    {\n      \"term\": \"Immunopeptidome\",\n      \"definition\": \"All peptides displayed on cell surfaces by MHC proteins for recognition by immune T cells.\"\n    },\n    {\n      \"term\": \"Type I interferon\",\n      \"definition\": \"A cytokine pathway that activates innate and adaptive immunity, including improved antigen presentation.\"\n    },\n    {\n      \"term\": \"Retrospective cohort\",\n      \"definition\": \"A study that analyzes previously collected patient data rather than assigning treatments prospectively.\"\n    }\n  ],\n  \"open_questions\": [\n    \"How do these findings translate in prospective, randomized human trials with predefined endpoints?\",\n    \"What are the optimal doses and schedules for intratumoral mRNA dosing with anti-PD-L1?\",\n    \"Which patient groups, defined by biomarkers, benefit most from this approach?\",\n    \"Can similar effects be reproduced across different tumor types and treatment histories.\"\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/public_summary.json",
            "callId": "call_gNlVou9gHvGJS2bWdysg6p5w"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/public_summary.json",
              "content": "{\n  \"headline\": \"Intratumoral mRNA vaccines may improve immune checkpoint therapy response signals.\",\n  \"plain_language_summary\": \"This study reports that injecting mRNA vaccine directly into tumors appears to increase immune signaling and immune-cell visibility markers in mice, especially when paired with anti-PD-L1 treatment. In preclinical work, mice receiving combination strategies showed larger tumor antigen display and stronger immune activation markers than comparator conditions. In a retrospective human cohort of 130 ICI-treated patients, 43 had prior SARS-CoV-2 mRNA vaccination and 87 had not; the comparison showed a p-value of 0.01 favoring vaccinated patients. Researchers also reported that non-mRNA particle controls and interferon-blocking experiments supported the mechanism involving type I interferon. The report proposes this as a translational strategy but stresses that retrospective, non-randomized human data cannot replace randomized clinical trials for causal confirmation.\",\n  \"what_is_new\": [\n    \"The work combines mouse mechanistic experiments and a human retrospective cohort in one coherent translational framework.\",\n    \"It links type I interferon pathway activation to improved antigen presentation and checkpoint sensitization.\",\n    \"The study adds control and perturbation experiments, including anti-IFNAR1 and non-mRNA lipid controls.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"This is a retrospective human analysis, so treatment selection and confounding may affect apparent survival differences.\",\n    \"Vaccination timing varied across patients, and treatment histories were heterogeneous.\",\n    \"Mouse models do not map perfectly to all human cancers, so observed preclinical benefit may not generalize widely.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"mRNA vaccine\",\n      \"definition\": \"An injected therapy delivering genetic instructions for cells to briefly make proteins and stimulate local immunity.\",\n      \"extra\": \"not used\"\n    },\n    {\n      \"term\": \"PD-L1\",\n      \"definition\": \"A suppressive immune checkpoint protein; blocking it can help T cells attack tumors.\" \n    },\n    {\n      \"term\": \"Retrospective cohort\",\n      \"definition\": \"A study that compares outcomes in existing groups after treatment has already been given.\"\n    },\n    {\n      \"term\": \"CD8+ T-cell\",\n      \"definition\": \"A cytotoxic immune cell type important for killing cancer cells when activated.\"\n    },\n    {\n      \"term\": \"Type I interferon\",\n      \"definition\": \"A class of immune molecules that enhance antiviral and anti-tumor immune programs, including antigen processing.\"\n    }\n  ],\n  \"open_questions\": [\n    \"What is the ideal clinical timing and sequencing of intratumoral mRNA vaccination with ICI?\",\n    \"Which specific tumor settings are most likely to benefit and which are unlikely?\",\n    \"What biomarkers can predict response and monitor on-treatment sensitization in patients?\"\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/public_summary.json",
            "callId": "call_cyOOQElt2vLR5JhX0p3DYsQN"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/public_summary.json",
              "content": "{\n  \"headline\": \"mRNA cancer vaccines can prime tumors for stronger checkpoint therapy responses.\",\n  \"plain_language_summary\": \"This study examined how intratumoral mRNA vaccination affects sensitivity to anti-PD-L1 treatment. In mice, the combination approach increased markers of immune presentation and immune activity, including larger fractions of tumor proteins in the immunopeptidome, greater MHC-I peptide representation, higher type I interferon response score, increased PD-L1 expression, and higher intratumoral CD8+ T-cell density. In a retrospective human cohort of 130 metastatic patients on ICI therapy, 43 had previous SARS-CoV-2 mRNA vaccination and 87 were unvaccinated; survival comparison favored the vaccinated group (p=0.01). The data also indicate specificity, with limited benefit in vaccine-only or ICI-only contexts and loss of sensitization when interferon signaling was blocked, supporting a proposed mechanistic chain. Because of confounding risk and cohort heterogeneity, the findings support further study, not immediate clinical adoption.\",\n  \"what_is_new\": [\n    \"The study integrates murine mechanistic work with human observational outcomes to support a translational hypothesis.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human study is retrospective and non-randomized, making causal interpretation of survival differences difficult.\",\n    \"Vaccination timing and prior treatment history varied across patients.\",\n    \"Findings from mouse models may not transfer directly to all human cancers.\",\n    \"Some mechanistic readouts were strongest in specific settings rather than uniformly across all tested models.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"mRNA vaccine\",\n      \"definition\": \"A therapy delivering messenger RNA to produce proteins that stimulate immune signaling locally in the tumor.\",\n      \"extra\": \"unused\"\n    },\n    {\n      \"term\": \"PD-L1\",\n      \"definition\": \"A molecule that can suppress T-cell function; anti-PD-L1 therapy blocks this suppression.\",\n      \"extra\": \"\"\n    },\n    {\n      \"term\": \"Immunopeptidome\",\n      \"definition\": \"The complete set of peptides presented by MHC molecules to immune cells.\" \n    },\n    {\n      \"term\": \"CD8+ T-cell\",\n      \"definition\": \"An immune cell that can directly kill tumor cells when activated.\" \n    }\n  ],\n  \"open_questions\": [\n    \"Which tumors and patient populations are most likely to benefit most in prospective trials?\",\n    \"What is the safest and most effective sequencing of intratumoral mRNA administration with anti-PD-L1?\",\n    \"Can biomarkers of interferon signaling reliably predict responders?\"\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/public_summary.json",
            "callId": "call_oG3694PszpvEp4cZ5gL91mMz"
          }
        ],
        "usage": {
          "promptTokens": 16806,
          "cachedTokens": 15744,
          "responseTokens": 3823,
          "thinkingTokens": 0,
          "totalTokens": 20629
        },
        "costUsd": 0.0083051
      },
      {
        "step": 22,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/public_summary.json",
              "offset": 0,
              "limit": 500
            },
            "output": "L1: {\nL2:   \"headline\": \"Intratumoral mRNA vaccines may improve immune checkpoint therapy response signals.\",\nL3:   \"plain_language_summary\": \"This study reports that injecting mRNA vaccine directly into tumors appears to increase immune signaling and immune-cell visibility markers in mice, especially when paired with anti-PD-L1 treatment. In preclinical work, mice receiving combination strategies showed larger tumor antigen display and stronger immune activation markers than comparator conditions. In a retrospective human cohort of 130 ICI-treated patients, 43 had prior SARS-CoV-2 mRNA vaccination and 87 h\nL4:   \"what_is_new\": [\nL5:     \"The work combines mouse mechanistic experiments and a human retrospective cohort in one coherent translational framework.\",\nL6:     \"It links type I interferon pathway activation to improved antigen presentation and checkpoint sensitization.\",\nL7:     \"The study adds control and perturbation experiments, including anti-IFNAR1 and non-mRNA lipid controls.\"\nL8:   ],\nL9:   \"why_caution_is_needed\": [\nL10:     \"This is a retrospective human analysis, so treatment selection and confounding may affect apparent survival differences.\",\nL11:     \"Vaccination timing varied across patients, and treatment histories were heterogeneous.\",\nL12:     \"Mouse models do not map perfectly to all human cancers, so observed preclinical benefit may not generalize widely.\"\nL13:   ],\nL14:   \"glossary\": [\nL15:     {\nL16:       \"term\": \"mRNA vaccine\",\nL17:       \"definition\": \"An injected therapy delivering genetic instructions for cells to briefly make proteins and stimulate local immunity.\",\nL18:       \"extra\": \"not used\"\nL19:     },\nL20:     {\nL21:       \"term\": \"PD-L1\",\nL22:       \"definition\": \"A suppressive immune checkpoint protein; blocking it can help T cells attack tumors.\" \nL23:     },\nL24:     {\nL25:       \"term\": \"Retrospective cohort\",\nL26:       \"definition\": \"A study that compares outcomes in existing groups after treatment has already been given.\"\nL27:     },\nL28:     {\nL29:       \"term\": \"CD8+ T-cell\",\nL30:       \"definition\": \"A cytotoxic immune cell type important for killing cancer cells when activated.\"\nL31:     },\nL32:     {\nL33:       \"term\": \"Type I interferon\",\nL34:       \"definition\": \"A class of immune molecules that enhance antiviral and anti-tumor immune programs, including antigen processing.\"\nL35:     }\nL36:   ],\nL37:   \"open_questions\": [\nL38:     \"What is the ideal clinical timing and sequencing of intratumoral mRNA vaccination with ICI?\",\nL39:     \"Which specific tumor settings are most likely to benefit and which are unlikely?\",\nL40:     \"What biomarkers can predict response and monitor on-treatment sensitization in patients?\"\nL41:   ]\nL42: }\nL43: ptides shown on cell surfaces by MHC molecules for immune recognition.\"\nL44:     }\nL45:   ],\nL46:   \"open_questions\": [\nL47:     \"Which cancer types will show the strongest clinical benefit in prospective testing?\",\nL48:     \"What is the optimal schedule of intratumoral mRNA administration relative to ICI start and dosing?\",\nL49:     \"Can biomarker profiles predict which patients can benefit most from this sensitization strategy?\",\nL50:     \"What are the durability and long-term safety implications of intratumoral mRNA vaccination combined with checkpoint therapy?\"\nL51:   ]\nL52: }\nL53: n_questions\": [\nL54:     \"Which prospective trial design will best test whether these preclinical mechanistic findings translate to specific human cancers?\",\nL55:     \"Can efficacy be reproduced in a randomized setting with standardized vaccination timing relative to ICI treatment?\",\nL56:     \"What biomarkers best identify patients most likely to benefit from intratumoral mRNA vaccination sensitization?\",\nL57:     \"How durable are responses and what are potential resistance mechanisms after initial sensitization occurs?\"\nL58:   ]\nL59: }",
            "callId": "call_DLi5ByDBeLVukdQOVEF75Vjl"
          }
        ],
        "usage": {
          "promptTokens": 20726,
          "cachedTokens": 16640,
          "responseTokens": 30,
          "thinkingTokens": 0,
          "totalTokens": 20756
        },
        "costUsd": 0.0014975
      },
      {
        "step": 23,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/study_overview.json",
              "offset": 0,
              "limit": 400
            },
            "output": "L1: {\nL2:   \"paper\": {\nL3:     \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\nL4:     \"doi\": \"10.1038/s41586-025-09006-8\",\nL5:     \"publication_year\": 2025,\nL6:     \"domain\": \"oncology-immunology\",\nL7:     \"study_type\": \"preclinical+retrospective\"\nL8:   },\nL9:   \"core_question\": \"Can intratumoral mRNA vaccination increase tumor immunogenicity and improve response to anti-PD-L1 immune checkpoint blockade in mice and in retrospective human ICI-treated patients?\",\nL10:   \"datasets_or_cohorts\": [\nL11:     {\nL12:       \"id\": \"mouse-efficacy-cohort\",\nL13:       \"label\": \"Mouse efficacy cohort\",\nL14:       \"sample_size_or_observations\": \"78 mice\",\nL15:       \"description\": \"Preclinical mice with tumor-bearing models receiving the combination therapy arm across pooled repeat experiments.\"\nL16:     },\nL17:     {\nL18:       \"id\": \"mouse-control-cohort\",\nL19:       \"label\": \"Mouse control cohort\",\nL20:       \"sample_size_or_observations\": \"84 mice\",\nL21:       \"description\": \"Matched preclinical controls (vaccine only, ICI only, and vehicle), pooled across repeat mouse experiments.\"\nL22:     },\nL23:     {\nL24:       \"id\": \"human-retrospective-cohort\",\nL25:       \"label\": \"Human retrospective cohort\",\nL26:       \"sample_size_or_observations\": \"130 patients\",\nL27:       \"description\": \"Retrospective cohort of metastatic patients receiving ICI, stratified by prior SARS-CoV-2 mRNA vaccination status.\"\nL28:     },\nL29:     {\nL30:       \"id\": \"human-vaccinated-subgroup\",\nL31:       \"label\": \"Human vaccinated subgroup\",\nL32:       \"sample_size_or_observations\": \"43 patients\",\nL33:       \"description\": \"Retrospective vaccinated subgroup within the human cohort used for survival comparison versus unvaccinated patients.\"\nL34:     },\nL35:     {\nL36:       \"id\": \"human-unvaccinated-subgroup\",\nL37:       \"label\": \"Human unvaccinated subgroup\",\nL38:       \"sample_size_or_observations\": \"87 patients\",\nL39:       \"description\": \"Retrospective unvaccinated comparator subgroup within the same ICI-treated metastatic patient cohort.\"\nL40:     }\nL41:   ],\nL42:   \"major_limitations\": [\nL43:     \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\nL44:     \"Vaccination timing relative to ICI initiation varied across patients in the retrospective human cohort.\",\nL45:     \"Tumor-type mix and prior treatment-history heterogeneity limit direct causal interpretation of outcomes.\",\nL46:     \"Mouse model effects may not map one-to-one to all human tumors.\",\nL47:     \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\nL48:   ]\nL49: }",
            "callId": "call_jWq0FZhKi1GerM8iYDL1CCvq"
          }
        ],
        "usage": {
          "promptTokens": 21653,
          "cachedTokens": 20608,
          "responseTokens": 34,
          "thinkingTokens": 252,
          "totalTokens": 21939
        },
        "costUsd": 0.0013484500000000002
      },
      {
        "step": 24,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/public_summary.json",
              "offset": 0,
              "limit": 200
            },
            "output": "L1: {\nL2:   \"headline\": \"Intratumoral mRNA vaccines may improve immune checkpoint therapy response signals.\",\nL3:   \"plain_language_summary\": \"This study reports that injecting mRNA vaccine directly into tumors appears to increase immune signaling and immune-cell visibility markers in mice, especially when paired with anti-PD-L1 treatment. In preclinical work, mice receiving combination strategies showed larger tumor antigen display and stronger immune activation markers than comparator conditions. In a retrospective human cohort of 130 ICI-treated patients, 43 had prior SARS-CoV-2 mRNA vaccination and 87 h\nL4:   \"what_is_new\": [\nL5:     \"The work combines mouse mechanistic experiments and a human retrospective cohort in one coherent translational framework.\",\nL6:     \"It links type I interferon pathway activation to improved antigen presentation and checkpoint sensitization.\",\nL7:     \"The study adds control and perturbation experiments, including anti-IFNAR1 and non-mRNA lipid controls.\"\nL8:   ],\nL9:   \"why_caution_is_needed\": [\nL10:     \"This is a retrospective human analysis, so treatment selection and confounding may affect apparent survival differences.\",\nL11:     \"Vaccination timing varied across patients, and treatment histories were heterogeneous.\",\nL12:     \"Mouse models do not map perfectly to all human cancers, so observed preclinical benefit may not generalize widely.\"\nL13:   ],\nL14:   \"glossary\": [\nL15:     {\nL16:       \"term\": \"mRNA vaccine\",\nL17:       \"definition\": \"An injected therapy delivering genetic instructions for cells to briefly make proteins and stimulate local immunity.\",\nL18:       \"extra\": \"not used\"\nL19:     },\nL20:     {\nL21:       \"term\": \"PD-L1\",\nL22:       \"definition\": \"A suppressive immune checkpoint protein; blocking it can help T cells attack tumors.\" \nL23:     },\nL24:     {\nL25:       \"term\": \"Retrospective cohort\",\nL26:       \"definition\": \"A study that compares outcomes in existing groups after treatment has already been given.\"\nL27:     },\nL28:     {\nL29:       \"term\": \"CD8+ T-cell\",\nL30:       \"definition\": \"A cytotoxic immune cell type important for killing cancer cells when activated.\"\nL31:     },\nL32:     {\nL33:       \"term\": \"Type I interferon\",\nL34:       \"definition\": \"A class of immune molecules that enhance antiviral and anti-tumor immune programs, including antigen processing.\"\nL35:     }\nL36:   ],\nL37:   \"open_questions\": [\nL38:     \"What is the ideal clinical timing and sequencing of intratumoral mRNA vaccination with ICI?\",\nL39:     \"Which specific tumor settings are most likely to benefit and which are unlikely?\",\nL40:     \"What biomarkers can predict response and monitor on-treatment sensitization in patients?\"\nL41:   ]\nL42: }\nL43: ptides shown on cell surfaces by MHC molecules for immune recognition.\"\nL44:     }\nL45:   ],\nL46:   \"open_questions\": [\nL47:     \"Which cancer types will show the strongest clinical benefit in prospective testing?\",\nL48:     \"What is the optimal schedule of intratumoral mRNA administration relative to ICI start and dosing?\",\nL49:     \"Can biomarker profiles predict which patients can benefit most from this sensitization strategy?\",\nL50:     \"What are the durability and long-term safety implications of intratumoral mRNA vaccination combined with checkpoint therapy?\"\nL51:   ]\nL52: }\nL53: n_questions\": [\nL54:     \"Which prospective trial design will best test whether these preclinical mechanistic findings translate to specific human cancers?\",\nL55:     \"Can efficacy be reproduced in a randomized setting with standardized vaccination timing relative to ICI treatment?\",\nL56:     \"What biomarkers best identify patients most likely to benefit from intratumoral mRNA vaccination sensitization?\",\nL57:     \"How durable are responses and what are potential resistance mechanisms after initial sensitization occurs?\"\nL58:   ]\nL59: }",
            "callId": "call_s4q8xqK4xGvvAknilKNUZA1y"
          }
        ],
        "usage": {
          "promptTokens": 22399,
          "cachedTokens": 21504,
          "responseTokens": 32,
          "thinkingTokens": 233,
          "totalTokens": 22664
        },
        "costUsd": 0.0012913500000000001
      },
      {
        "step": 25,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/study_overview.json",
              "offset": 0,
              "limit": 200
            },
            "output": "L1: {\nL2:   \"paper\": {\nL3:     \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\nL4:     \"doi\": \"10.1038/s41586-025-09006-8\",\nL5:     \"publication_year\": 2025,\nL6:     \"domain\": \"oncology-immunology\",\nL7:     \"study_type\": \"preclinical+retrospective\"\nL8:   },\nL9:   \"core_question\": \"Can intratumoral mRNA vaccination increase tumor immunogenicity and improve response to anti-PD-L1 immune checkpoint blockade in mice and in retrospective human ICI-treated patients?\",\nL10:   \"datasets_or_cohorts\": [\nL11:     {\nL12:       \"id\": \"mouse-efficacy-cohort\",\nL13:       \"label\": \"Mouse efficacy cohort\",\nL14:       \"sample_size_or_observations\": \"78 mice\",\nL15:       \"description\": \"Preclinical mice with tumor-bearing models receiving the combination therapy arm across pooled repeat experiments.\"\nL16:     },\nL17:     {\nL18:       \"id\": \"mouse-control-cohort\",\nL19:       \"label\": \"Mouse control cohort\",\nL20:       \"sample_size_or_observations\": \"84 mice\",\nL21:       \"description\": \"Matched preclinical controls (vaccine only, ICI only, and vehicle), pooled across repeat mouse experiments.\"\nL22:     },\nL23:     {\nL24:       \"id\": \"human-retrospective-cohort\",\nL25:       \"label\": \"Human retrospective cohort\",\nL26:       \"sample_size_or_observations\": \"130 patients\",\nL27:       \"description\": \"Retrospective cohort of metastatic patients receiving ICI, stratified by prior SARS-CoV-2 mRNA vaccination status.\"\nL28:     },\nL29:     {\nL30:       \"id\": \"human-vaccinated-subgroup\",\nL31:       \"label\": \"Human vaccinated subgroup\",\nL32:       \"sample_size_or_observations\": \"43 patients\",\nL33:       \"description\": \"Retrospective vaccinated subgroup within the human cohort used for survival comparison versus unvaccinated patients.\"\nL34:     },\nL35:     {\nL36:       \"id\": \"human-unvaccinated-subgroup\",\nL37:       \"label\": \"Human unvaccinated subgroup\",\nL38:       \"sample_size_or_observations\": \"87 patients\",\nL39:       \"description\": \"Retrospective unvaccinated comparator subgroup within the same ICI-treated metastatic patient cohort.\"\nL40:     }\nL41:   ],\nL42:   \"major_limitations\": [\nL43:     \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\nL44:     \"Vaccination timing relative to ICI initiation varied across patients in the retrospective human cohort.\",\nL45:     \"Tumor-type mix and prior treatment-history heterogeneity limit direct causal interpretation of outcomes.\",\nL46:     \"Mouse model effects may not map one-to-one to all human tumors.\",\nL47:     \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\nL48:   ]\nL49: }",
            "callId": "call_H2ke4JHXDD1mO7IfAQeu1TdE"
          }
        ],
        "usage": {
          "promptTokens": 23326,
          "cachedTokens": 22272,
          "responseTokens": 34,
          "thinkingTokens": 548,
          "totalTokens": 23908
        },
        "costUsd": 0.0019843
      },
      {
        "step": 26,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/public_summary.json",
              "content": "{\n  \"headline\": \"Intratumoral mRNA vaccination may sensitize tumors to checkpoint blockade\",\n  \"plain_language_summary\": \"This study tested whether injecting mRNA vaccines directly into tumors can make cancers more visible to the immune system and improve responses to anti-PD-L1 therapy. In several mouse tumor models, the combination arm showed stronger evidence of immune activation than controls: broader antigen representation, stronger MHC-I peptide presentation, higher type I interferon response, increased PD-L1 expression, and higher intratumoral CD8+ T-cell density. Control analyses reported limited benefit in vaccine-only or ICI-only settings and loss of effect when type I interferon signaling was blocked, supporting a mechanistic pathway. In a retrospective cohort of 130 metastatic patients treated with ICIs, 43 had prior SARS-CoV-2 mRNA vaccination and 87 had not, with a reported survival p-value of 0.01 favoring the vaccinated subgroup. The authors therefore propose a translational sensitization strategy but stress that retrospective, non-randomized evidence is not sufficient to change clinical protocols without prospective randomized confirmation.\",\n  \"what_is_new\": [\n    \"The work links preclinical mechanistic studies to a human retrospective association in one translational framework.\",\n    \"It reports a required role for type I interferon signaling, including loss of sensitization when anti-IFNAR1 is applied.\",\n    \"The study documents coordinated quantitative changes in antigen presentation, interferon signaling, PD-L1, and T-cell infiltration with intratumoral mRNA vaccination.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human analysis is retrospective and non-randomized, so confounding can affect apparent survival differences.\",\n    \"Vaccination timing relative to ICI initiation varied across patients and may influence apparent benefit.\",\n    \"The retrospective cohort was heterogeneous in tumor types and treatment histories, limiting direct causal interpretation.\",\n    \"Mouse-model findings may not translate equally across all human cancers.\",\n    \"Some mechanistic readouts were strongest only in specific models rather than uniformly across all tests.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"mRNA vaccine\",\n      \"definition\": \"A therapy that uses messenger RNA to direct cells to make proteins and trigger local immune activation.\"\n    },\n    {\n      \"term\": \"PD-L1\",\n      \"definition\": \"A checkpoint protein that can suppress T-cell killing; blocking it can increase anti-tumor immune activity.\"\n    },\n    {\n      \"term\": \"ICI\",\n      \"definition\": \"Immune checkpoint inhibitor, a drug class that releases brakes on immune cells to improve anti-cancer responses.\"\n    },\n    {\n      \"term\": \"Retrospective cohort\",\n      \"definition\": \"A study of existing patient records where treatment groups are compared after care has already occurred.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Can these tumor-sensitization effects be reproduced in randomized human trials with preplanned timing and endpoints?\",\n    \"Which tumor types and clinical settings are most likely to benefit from intratumoral mRNA sensitization?\",\n    \"Can biomarkers of interferon signaling or antigen presentation identify likely responders before treatment?\",\n    \"What are the durability and safety implications of combining intratumoral mRNA with checkpoint blockade over longer follow-up?\"\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/public_summary.json",
            "callId": "call_dswAVcUFfTFJjNt7ZG7Yqyvs"
          }
        ],
        "usage": {
          "promptTokens": 24072,
          "cachedTokens": 23168,
          "responseTokens": 775,
          "thinkingTokens": 1624,
          "totalTokens": 26471
        },
        "costUsd": 0.0056032
      },
      {
        "step": 27,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/study_overview.json",
              "offset": 0,
              "limit": 500
            },
            "output": "L1: {\nL2:   \"paper\": {\nL3:     \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\nL4:     \"doi\": \"10.1038/s41586-025-09006-8\",\nL5:     \"publication_year\": 2025,\nL6:     \"domain\": \"oncology-immunology\",\nL7:     \"study_type\": \"preclinical+retrospective\"\nL8:   },\nL9:   \"core_question\": \"Can intratumoral mRNA vaccination increase tumor immunogenicity and improve response to anti-PD-L1 immune checkpoint blockade in mice and in retrospective human ICI-treated patients?\",\nL10:   \"datasets_or_cohorts\": [\nL11:     {\nL12:       \"id\": \"mouse-efficacy-cohort\",\nL13:       \"label\": \"Mouse efficacy cohort\",\nL14:       \"sample_size_or_observations\": \"78 mice\",\nL15:       \"description\": \"Preclinical mice with tumor-bearing models receiving the combination therapy arm across pooled repeat experiments.\"\nL16:     },\nL17:     {\nL18:       \"id\": \"mouse-control-cohort\",\nL19:       \"label\": \"Mouse control cohort\",\nL20:       \"sample_size_or_observations\": \"84 mice\",\nL21:       \"description\": \"Matched preclinical controls (vaccine only, ICI only, and vehicle), pooled across repeat mouse experiments.\"\nL22:     },\nL23:     {\nL24:       \"id\": \"human-retrospective-cohort\",\nL25:       \"label\": \"Human retrospective cohort\",\nL26:       \"sample_size_or_observations\": \"130 patients\",\nL27:       \"description\": \"Retrospective cohort of metastatic patients receiving ICI, stratified by prior SARS-CoV-2 mRNA vaccination status.\"\nL28:     },\nL29:     {\nL30:       \"id\": \"human-vaccinated-subgroup\",\nL31:       \"label\": \"Human vaccinated subgroup\",\nL32:       \"sample_size_or_observations\": \"43 patients\",\nL33:       \"description\": \"Retrospective vaccinated subgroup within the human cohort used for survival comparison versus unvaccinated patients.\"\nL34:     },\nL35:     {\nL36:       \"id\": \"human-unvaccinated-subgroup\",\nL37:       \"label\": \"Human unvaccinated subgroup\",\nL38:       \"sample_size_or_observations\": \"87 patients\",\nL39:       \"description\": \"Retrospective unvaccinated comparator subgroup within the same ICI-treated metastatic patient cohort.\"\nL40:     }\nL41:   ],\nL42:   \"major_limitations\": [\nL43:     \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\nL44:     \"Vaccination timing relative to ICI initiation varied across patients in the retrospective human cohort.\",\nL45:     \"Tumor-type mix and prior treatment-history heterogeneity limit direct causal interpretation of outcomes.\",\nL46:     \"Mouse model effects may not map one-to-one to all human tumors.\",\nL47:     \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\nL48:   ]\nL49: }",
            "callId": "call_s16mhMo6QxEpE5nx1iLnsgHL"
          }
        ],
        "usage": {
          "promptTokens": 24864,
          "cachedTokens": 23936,
          "responseTokens": 34,
          "thinkingTokens": 158,
          "totalTokens": 25056
        },
        "costUsd": 0.0012144
      },
      {
        "step": 28,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/public_summary.json",
              "offset": 0,
              "limit": 300
            },
            "output": "L1: {\nL2:   \"headline\": \"Intratumoral mRNA vaccination may sensitize tumors to checkpoint blockade\",\nL3:   \"plain_language_summary\": \"This study tested whether injecting mRNA vaccines directly into tumors can make cancers more visible to the immune system and improve responses to anti-PD-L1 therapy. In several mouse tumor models, the combination arm showed stronger evidence of immune activation than controls: broader antigen representation, stronger MHC-I peptide presentation, higher type I interferon response, increased PD-L1 expression, and higher intratumoral CD8+ T-cell density. Control analyse\nL4:   \"what_is_new\": [\nL5:     \"The work links preclinical mechanistic studies to a human retrospective association in one translational framework.\",\nL6:     \"It reports a required role for type I interferon signaling, including loss of sensitization when anti-IFNAR1 is applied.\",\nL7:     \"The study documents coordinated quantitative changes in antigen presentation, interferon signaling, PD-L1, and T-cell infiltration with intratumoral mRNA vaccination.\"\nL8:   ],\nL9:   \"why_caution_is_needed\": [\nL10:     \"The human analysis is retrospective and non-randomized, so confounding can affect apparent survival differences.\",\nL11:     \"Vaccination timing relative to ICI initiation varied across patients and may influence apparent benefit.\",\nL12:     \"The retrospective cohort was heterogeneous in tumor types and treatment histories, limiting direct causal interpretation.\",\nL13:     \"Mouse-model findings may not translate equally across all human cancers.\",\nL14:     \"Some mechanistic readouts were strongest only in specific models rather than uniformly across all tests.\"\nL15:   ],\nL16:   \"glossary\": [\nL17:     {\nL18:       \"term\": \"mRNA vaccine\",\nL19:       \"definition\": \"A therapy that uses messenger RNA to direct cells to make proteins and trigger local immune activation.\"\nL20:     },\nL21:     {\nL22:       \"term\": \"PD-L1\",\nL23:       \"definition\": \"A checkpoint protein that can suppress T-cell killing; blocking it can increase anti-tumor immune activity.\"\nL24:     },\nL25:     {\nL26:       \"term\": \"ICI\",\nL27:       \"definition\": \"Immune checkpoint inhibitor, a drug class that releases brakes on immune cells to improve anti-cancer responses.\"\nL28:     },\nL29:     {\nL30:       \"term\": \"Retrospective cohort\",\nL31:       \"definition\": \"A study of existing patient records where treatment groups are compared after care has already occurred.\"\nL32:     }\nL33:   ],\nL34:   \"open_questions\": [\nL35:     \"Can these tumor-sensitization effects be reproduced in randomized human trials with preplanned timing and endpoints?\",\nL36:     \"Which tumor types and clinical settings are most likely to benefit from intratumoral mRNA sensitization?\",\nL37:     \"Can biomarkers of interferon signaling or antigen presentation identify likely responders before treatment?\",\nL38:     \"What are the durability and safety implications of combining intratumoral mRNA with checkpoint blockade over longer follow-up?\"\nL39:   ]\nL40: }",
            "callId": "call_WGyQxsY1rmgoT8P6Tc6jWylS"
          }
        ],
        "usage": {
          "promptTokens": 25610,
          "cachedTokens": 24704,
          "responseTokens": 32,
          "thinkingTokens": 114,
          "totalTokens": 25756
        },
        "costUsd": 0.0011361000000000001
      },
      {
        "step": 29,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/public_summary.json",
              "offset": 0,
              "limit": 500
            },
            "output": "L1: {\nL2:   \"headline\": \"Intratumoral mRNA vaccination may sensitize tumors to checkpoint blockade\",\nL3:   \"plain_language_summary\": \"This study tested whether injecting mRNA vaccines directly into tumors can make cancers more visible to the immune system and improve responses to anti-PD-L1 therapy. In several mouse tumor models, the combination arm showed stronger evidence of immune activation than controls: broader antigen representation, stronger MHC-I peptide presentation, higher type I interferon response, increased PD-L1 expression, and higher intratumoral CD8+ T-cell density. Control analyse\nL4:   \"what_is_new\": [\nL5:     \"The work links preclinical mechanistic studies to a human retrospective association in one translational framework.\",\nL6:     \"It reports a required role for type I interferon signaling, including loss of sensitization when anti-IFNAR1 is applied.\",\nL7:     \"The study documents coordinated quantitative changes in antigen presentation, interferon signaling, PD-L1, and T-cell infiltration with intratumoral mRNA vaccination.\"\nL8:   ],\nL9:   \"why_caution_is_needed\": [\nL10:     \"The human analysis is retrospective and non-randomized, so confounding can affect apparent survival differences.\",\nL11:     \"Vaccination timing relative to ICI initiation varied across patients and may influence apparent benefit.\",\nL12:     \"The retrospective cohort was heterogeneous in tumor types and treatment histories, limiting direct causal interpretation.\",\nL13:     \"Mouse-model findings may not translate equally across all human cancers.\",\nL14:     \"Some mechanistic readouts were strongest only in specific models rather than uniformly across all tests.\"\nL15:   ],\nL16:   \"glossary\": [\nL17:     {\nL18:       \"term\": \"mRNA vaccine\",\nL19:       \"definition\": \"A therapy that uses messenger RNA to direct cells to make proteins and trigger local immune activation.\"\nL20:     },\nL21:     {\nL22:       \"term\": \"PD-L1\",\nL23:       \"definition\": \"A checkpoint protein that can suppress T-cell killing; blocking it can increase anti-tumor immune activity.\"\nL24:     },\nL25:     {\nL26:       \"term\": \"ICI\",\nL27:       \"definition\": \"Immune checkpoint inhibitor, a drug class that releases brakes on immune cells to improve anti-cancer responses.\"\nL28:     },\nL29:     {\nL30:       \"term\": \"Retrospective cohort\",\nL31:       \"definition\": \"A study of existing patient records where treatment groups are compared after care has already occurred.\"\nL32:     }\nL33:   ],\nL34:   \"open_questions\": [\nL35:     \"Can these tumor-sensitization effects be reproduced in randomized human trials with preplanned timing and endpoints?\",\nL36:     \"Which tumor types and clinical settings are most likely to benefit from intratumoral mRNA sensitization?\",\nL37:     \"Can biomarkers of interferon signaling or antigen presentation identify likely responders before treatment?\",\nL38:     \"What are the durability and safety implications of combining intratumoral mRNA with checkpoint blockade over longer follow-up?\"\nL39:   ]\nL40: }",
            "callId": "call_Y7OdD2CsUXSYF5gAdmg51vyX"
          }
        ],
        "usage": {
          "promptTokens": 26334,
          "cachedTokens": 25472,
          "responseTokens": 32,
          "thinkingTokens": 494,
          "totalTokens": 26860
        },
        "costUsd": 0.0019043
      },
      {
        "step": 30,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/study_overview.json",
              "offset": 0,
              "limit": 800
            },
            "output": "L1: {\nL2:   \"paper\": {\nL3:     \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\nL4:     \"doi\": \"10.1038/s41586-025-09006-8\",\nL5:     \"publication_year\": 2025,\nL6:     \"domain\": \"oncology-immunology\",\nL7:     \"study_type\": \"preclinical+retrospective\"\nL8:   },\nL9:   \"core_question\": \"Can intratumoral mRNA vaccination increase tumor immunogenicity and improve response to anti-PD-L1 immune checkpoint blockade in mice and in retrospective human ICI-treated patients?\",\nL10:   \"datasets_or_cohorts\": [\nL11:     {\nL12:       \"id\": \"mouse-efficacy-cohort\",\nL13:       \"label\": \"Mouse efficacy cohort\",\nL14:       \"sample_size_or_observations\": \"78 mice\",\nL15:       \"description\": \"Preclinical mice with tumor-bearing models receiving the combination therapy arm across pooled repeat experiments.\"\nL16:     },\nL17:     {\nL18:       \"id\": \"mouse-control-cohort\",\nL19:       \"label\": \"Mouse control cohort\",\nL20:       \"sample_size_or_observations\": \"84 mice\",\nL21:       \"description\": \"Matched preclinical controls (vaccine only, ICI only, and vehicle), pooled across repeat mouse experiments.\"\nL22:     },\nL23:     {\nL24:       \"id\": \"human-retrospective-cohort\",\nL25:       \"label\": \"Human retrospective cohort\",\nL26:       \"sample_size_or_observations\": \"130 patients\",\nL27:       \"description\": \"Retrospective cohort of metastatic patients receiving ICI, stratified by prior SARS-CoV-2 mRNA vaccination status.\"\nL28:     },\nL29:     {\nL30:       \"id\": \"human-vaccinated-subgroup\",\nL31:       \"label\": \"Human vaccinated subgroup\",\nL32:       \"sample_size_or_observations\": \"43 patients\",\nL33:       \"description\": \"Retrospective vaccinated subgroup within the human cohort used for survival comparison versus unvaccinated patients.\"\nL34:     },\nL35:     {\nL36:       \"id\": \"human-unvaccinated-subgroup\",\nL37:       \"label\": \"Human unvaccinated subgroup\",\nL38:       \"sample_size_or_observations\": \"87 patients\",\nL39:       \"description\": \"Retrospective unvaccinated comparator subgroup within the same ICI-treated metastatic patient cohort.\"\nL40:     }\nL41:   ],\nL42:   \"major_limitations\": [\nL43:     \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\nL44:     \"Vaccination timing relative to ICI initiation varied across patients in the retrospective human cohort.\",\nL45:     \"Tumor-type mix and prior treatment-history heterogeneity limit direct causal interpretation of outcomes.\",\nL46:     \"Mouse model effects may not map one-to-one to all human tumors.\",\nL47:     \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\nL48:   ]\nL49: }",
            "callId": "call_XY09v0uK5IYcGu5tscoVSQm4"
          }
        ],
        "usage": {
          "promptTokens": 27058,
          "cachedTokens": 26240,
          "responseTokens": 34,
          "thinkingTokens": 211,
          "totalTokens": 27303
        },
        "costUsd": 0.0013505
      },
      {
        "step": 31,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/public_summary.json",
              "offset": 0,
              "limit": 600
            },
            "output": "L1: {\nL2:   \"headline\": \"Intratumoral mRNA vaccination may sensitize tumors to checkpoint blockade\",\nL3:   \"plain_language_summary\": \"This study tested whether injecting mRNA vaccines directly into tumors can make cancers more visible to the immune system and improve responses to anti-PD-L1 therapy. In several mouse tumor models, the combination arm showed stronger evidence of immune activation than controls: broader antigen representation, stronger MHC-I peptide presentation, higher type I interferon response, increased PD-L1 expression, and higher intratumoral CD8+ T-cell density. Control analyse\nL4:   \"what_is_new\": [\nL5:     \"The work links preclinical mechanistic studies to a human retrospective association in one translational framework.\",\nL6:     \"It reports a required role for type I interferon signaling, including loss of sensitization when anti-IFNAR1 is applied.\",\nL7:     \"The study documents coordinated quantitative changes in antigen presentation, interferon signaling, PD-L1, and T-cell infiltration with intratumoral mRNA vaccination.\"\nL8:   ],\nL9:   \"why_caution_is_needed\": [\nL10:     \"The human analysis is retrospective and non-randomized, so confounding can affect apparent survival differences.\",\nL11:     \"Vaccination timing relative to ICI initiation varied across patients and may influence apparent benefit.\",\nL12:     \"The retrospective cohort was heterogeneous in tumor types and treatment histories, limiting direct causal interpretation.\",\nL13:     \"Mouse-model findings may not translate equally across all human cancers.\",\nL14:     \"Some mechanistic readouts were strongest only in specific models rather than uniformly across all tests.\"\nL15:   ],\nL16:   \"glossary\": [\nL17:     {\nL18:       \"term\": \"mRNA vaccine\",\nL19:       \"definition\": \"A therapy that uses messenger RNA to direct cells to make proteins and trigger local immune activation.\"\nL20:     },\nL21:     {\nL22:       \"term\": \"PD-L1\",\nL23:       \"definition\": \"A checkpoint protein that can suppress T-cell killing; blocking it can increase anti-tumor immune activity.\"\nL24:     },\nL25:     {\nL26:       \"term\": \"ICI\",\nL27:       \"definition\": \"Immune checkpoint inhibitor, a drug class that releases brakes on immune cells to improve anti-cancer responses.\"\nL28:     },\nL29:     {\nL30:       \"term\": \"Retrospective cohort\",\nL31:       \"definition\": \"A study of existing patient records where treatment groups are compared after care has already occurred.\"\nL32:     }\nL33:   ],\nL34:   \"open_questions\": [\nL35:     \"Can these tumor-sensitization effects be reproduced in randomized human trials with preplanned timing and endpoints?\",\nL36:     \"Which tumor types and clinical settings are most likely to benefit from intratumoral mRNA sensitization?\",\nL37:     \"Can biomarkers of interferon signaling or antigen presentation identify likely responders before treatment?\",\nL38:     \"What are the durability and safety implications of combining intratumoral mRNA with checkpoint blockade over longer follow-up?\"\nL39:   ]\nL40: }",
            "callId": "call_UOnrYJOek2we9qJAdXGxozcZ"
          }
        ],
        "usage": {
          "promptTokens": 27804,
          "cachedTokens": 26880,
          "responseTokens": 32,
          "thinkingTokens": 256,
          "totalTokens": 28092
        },
        "costUsd": 0.001479
      },
      {
        "step": 32,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/study_overview.json",
              "offset": 0,
              "limit": 1000
            },
            "output": "L1: {\nL2:   \"paper\": {\nL3:     \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\nL4:     \"doi\": \"10.1038/s41586-025-09006-8\",\nL5:     \"publication_year\": 2025,\nL6:     \"domain\": \"oncology-immunology\",\nL7:     \"study_type\": \"preclinical+retrospective\"\nL8:   },\nL9:   \"core_question\": \"Can intratumoral mRNA vaccination increase tumor immunogenicity and improve response to anti-PD-L1 immune checkpoint blockade in mice and in retrospective human ICI-treated patients?\",\nL10:   \"datasets_or_cohorts\": [\nL11:     {\nL12:       \"id\": \"mouse-efficacy-cohort\",\nL13:       \"label\": \"Mouse efficacy cohort\",\nL14:       \"sample_size_or_observations\": \"78 mice\",\nL15:       \"description\": \"Preclinical mice with tumor-bearing models receiving the combination therapy arm across pooled repeat experiments.\"\nL16:     },\nL17:     {\nL18:       \"id\": \"mouse-control-cohort\",\nL19:       \"label\": \"Mouse control cohort\",\nL20:       \"sample_size_or_observations\": \"84 mice\",\nL21:       \"description\": \"Matched preclinical controls (vaccine only, ICI only, and vehicle), pooled across repeat mouse experiments.\"\nL22:     },\nL23:     {\nL24:       \"id\": \"human-retrospective-cohort\",\nL25:       \"label\": \"Human retrospective cohort\",\nL26:       \"sample_size_or_observations\": \"130 patients\",\nL27:       \"description\": \"Retrospective cohort of metastatic patients receiving ICI, stratified by prior SARS-CoV-2 mRNA vaccination status.\"\nL28:     },\nL29:     {\nL30:       \"id\": \"human-vaccinated-subgroup\",\nL31:       \"label\": \"Human vaccinated subgroup\",\nL32:       \"sample_size_or_observations\": \"43 patients\",\nL33:       \"description\": \"Retrospective vaccinated subgroup within the human cohort used for survival comparison versus unvaccinated patients.\"\nL34:     },\nL35:     {\nL36:       \"id\": \"human-unvaccinated-subgroup\",\nL37:       \"label\": \"Human unvaccinated subgroup\",\nL38:       \"sample_size_or_observations\": \"87 patients\",\nL39:       \"description\": \"Retrospective unvaccinated comparator subgroup within the same ICI-treated metastatic patient cohort.\"\nL40:     }\nL41:   ],\nL42:   \"major_limitations\": [\nL43:     \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\nL44:     \"Vaccination timing relative to ICI initiation varied across patients in the retrospective human cohort.\",\nL45:     \"Tumor-type mix and prior treatment-history heterogeneity limit direct causal interpretation of outcomes.\",\nL46:     \"Mouse model effects may not map one-to-one to all human tumors.\",\nL47:     \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\nL48:   ]\nL49: }",
            "callId": "call_gJ2R0ePHOu0wtw3zeirMPO0g"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "offset": 0,
              "limit": 1200
            },
            "output": "L1: {\nL2:   \"findings\": [\nL3:     {\nL4:       \"id\": \"Q01\",\nL5:       \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\nL6:       \"value\": \"62.3%\",\nL7:       \"comparator_or_baseline\": \"37.3%\",\nL8:       \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination.\",\nL9:       \"evidence_line_refs\": [\"L28\"]\nL10:     },\nL11:     {\nL12:       \"id\": \"Q02\",\nL13:       \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\nL14:       \"value\": \"40.6%\",\nL15:       \"comparator_or_baseline\": \"20.6%\",\nL16:       \"interpretation\": \"Strong expansion of MHC-I-presented landscape.\",\nL17:       \"evidence_line_refs\": [\"L29\"]\nL18:     },\nL19:     {\nL20:       \"id\": \"Q03\",\nL21:       \"metric\": \"Retrospective human survival comparison p-value\",\nL22:       \"value\": \"p=0.01\",\nL23:       \"comparator_or_baseline\": \"N/A\",\nL24:       \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment.\",\nL25:       \"evidence_line_refs\": [\"L30\"]\nL26:     },\nL27:     {\nL28:       \"id\": \"Q04\",\nL29:       \"metric\": \"Type I interferon response score (normalized units)\",\nL30:       \"value\": \"3.1\",\nL31:       \"comparator_or_baseline\": \"1.0\",\nL32:       \"interpretation\": \"Marked induction after mRNA vaccination in tumors.\",\nL33:       \"evidence_line_refs\": [\"L31\"]\nL34:     },\nL35:     {\nL36:       \"id\": \"Q05\",\nL37:       \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\nL38:       \"value\": \"2.4x\",\nL39:       \"comparator_or_baseline\": \"1.0x\",\nL40:       \"interpretation\": \"Checkpoint axis became more targetable.\",\nL41:       \"evidence_line_refs\": [\"L32\"]\nL42:     },\nL43:     {\nL44:       \"id\": \"Q06\",\nL45:       \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\nL46:       \"value\": \"1.8x\",\nL47:       \"comparator_or_baseline\": \"1.0x\",\nL48:       \"interpretation\": \"Increased immune infiltration with combination therapy.\",\nL49:       \"evidence_line_refs\": [\"L33\"]\nL50:     }\nL51:   ],\nL52:   \"controls_or_null_results\": [\nL53:     {\nL54:       \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\nL55:       \"evidence_line_ref\": \"L36\"\nL56:     },\nL57:     {\nL58:       \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\nL59:       \"evidence_line_ref\": \"L37\"\nL60:     },\nL61:     {\nL62:       \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the observed sensitization effect.\",\nL63:       \"evidence_line_ref\": \"L38\"\nL64:     },\nL65:     {\nL66:       \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\nL67:       \"evidence_line_ref\": \"L39\"\nL68:     }\nL69:   ]\nL70: }",
            "callId": "call_8YKQRNhGrUJDZExgftPiru03"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "offset": 0,
              "limit": 1200
            },
            "output": "L1: {\nL2:   \"claims\": [\nL3:     {\nL4:       \"claim_id\": \"C01\",\nL5:       \"claim\": \"Intratumoral mRNA vaccination is proposed to increase tumor immunogenicity and improve anti-PD-L1 responses by expanding antigen presentation on MHC-I.\",\nL6:       \"strength\": \"moderate\",\nL7:       \"evidence\": [\nL8:         {\nL9:           \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\nL10:           \"line_ref\": \"L42\"\nL11:         },\nL12:         {\nL13:           \"quote\": \"A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\",\nL14:           \"line_ref\": \"L44\"\nL15:         }\nL16:       ],\nL17:       \"caveat\": \"The report notes that some mechanistic readouts were strongest in specific model systems, so effects may not be uniform across tumors.\"\nL18:     },\nL19:     {\nL20:       \"claim_id\": \"C02\",\nL21:       \"claim\": \"mRNA vaccination induces higher type I interferon activity in tumors than comparator conditions in the mouse experiments.\",\nL22:       \"strength\": \"strong\",\nL23:       \"evidence\": [\nL24:         {\nL25:           \"quote\": \"Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors\",\nL26:           \"line_ref\": \"L31\"\nL27:         },\nL28:         {\nL29:           \"quote\": \"Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination\",\nL30:           \"line_ref\": \"L28\"\nL31:         }\nL32:       ],\nL33:       \"caveat\": \"The table summarizes these values, and the report does not provide additional design details for each numerical comparison in this extract.\"\nL34:     },\nL35:     {\nL36:       \"claim_id\": \"C03\",\nL37:       \"claim\": \"Type I interferon signaling is necessary for the sensitization benefit in preclinical settings, because anti-IFNAR1 blockade abolished the benefit.\",\nL38:       \"strength\": \"strong\",\nL39:       \"evidence\": [\nL40:         {\nL41:           \"quote\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\nL42:           \"line_ref\": \"L39\"\nL43:         },\nL44:         {\nL45:           \"quote\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\nL46:           \"line_ref\": \"L38\"\nL47:         }\nL48:       ],\nL49:       \"caveat\": \"This is a mechanistic inference from preclinical perturbation controls and cannot by itself prove causality in patients.\"\nL50:     },\nL51:     {\nL52:       \"claim_id\": \"C04\",\nL53:       \"claim\": \"In the retrospective human cohort, prior SARS-CoV-2 mRNA vaccination was associated with improved survival under ICI treatment compared with no prior vaccination.\",\nL54:       \"strength\": \"tentative\",\nL55:       \"evidence\": [\nL56:         {\nL57:           \"quote\": \"Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment\",\nL58:           \"line_ref\": \"L30\"\nL59:         },\nL60:         {\nL61:           \"quote\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\nL62:           \"line_ref\": \"L49\"\nL63:         }\nL64:       ],\nL65:       \"caveat\": \"This analysis is retrospective with heterogeneous tumor types and variable vaccination timing, so unmeasured confounding may influence outcomes.\"\nL66:     }\nL67:   ]\nL68: }",
            "callId": "call_JJJQzhLbr4PRMSfW8qXJ3JtC"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/public_summary.json",
              "offset": 0,
              "limit": 1500
            },
            "output": "L1: {\nL2:   \"headline\": \"Intratumoral mRNA vaccination may sensitize tumors to checkpoint blockade\",\nL3:   \"plain_language_summary\": \"This study tested whether injecting mRNA vaccines directly into tumors can make cancers more visible to the immune system and improve responses to anti-PD-L1 therapy. In several mouse tumor models, the combination arm showed stronger evidence of immune activation than controls: broader antigen representation, stronger MHC-I peptide presentation, higher type I interferon response, increased PD-L1 expression, and higher intratumoral CD8+ T-cell density. Control analyse\nL4:   \"what_is_new\": [\nL5:     \"The work links preclinical mechanistic studies to a human retrospective association in one translational framework.\",\nL6:     \"It reports a required role for type I interferon signaling, including loss of sensitization when anti-IFNAR1 is applied.\",\nL7:     \"The study documents coordinated quantitative changes in antigen presentation, interferon signaling, PD-L1, and T-cell infiltration with intratumoral mRNA vaccination.\"\nL8:   ],\nL9:   \"why_caution_is_needed\": [\nL10:     \"The human analysis is retrospective and non-randomized, so confounding can affect apparent survival differences.\",\nL11:     \"Vaccination timing relative to ICI initiation varied across patients and may influence apparent benefit.\",\nL12:     \"The retrospective cohort was heterogeneous in tumor types and treatment histories, limiting direct causal interpretation.\",\nL13:     \"Mouse-model findings may not translate equally across all human cancers.\",\nL14:     \"Some mechanistic readouts were strongest only in specific models rather than uniformly across all tests.\"\nL15:   ],\nL16:   \"glossary\": [\nL17:     {\nL18:       \"term\": \"mRNA vaccine\",\nL19:       \"definition\": \"A therapy that uses messenger RNA to direct cells to make proteins and trigger local immune activation.\"\nL20:     },\nL21:     {\nL22:       \"term\": \"PD-L1\",\nL23:       \"definition\": \"A checkpoint protein that can suppress T-cell killing; blocking it can increase anti-tumor immune activity.\"\nL24:     },\nL25:     {\nL26:       \"term\": \"ICI\",\nL27:       \"definition\": \"Immune checkpoint inhibitor, a drug class that releases brakes on immune cells to improve anti-cancer responses.\"\nL28:     },\nL29:     {\nL30:       \"term\": \"Retrospective cohort\",\nL31:       \"definition\": \"A study of existing patient records where treatment groups are compared after care has already occurred.\"\nL32:     }\nL33:   ],\nL34:   \"open_questions\": [\nL35:     \"Can these tumor-sensitization effects be reproduced in randomized human trials with preplanned timing and endpoints?\",\nL36:     \"Which tumor types and clinical settings are most likely to benefit from intratumoral mRNA sensitization?\",\nL37:     \"Can biomarkers of interferon signaling or antigen presentation identify likely responders before treatment?\",\nL38:     \"What are the durability and safety implications of combining intratumoral mRNA with checkpoint blockade over longer follow-up?\"\nL39:   ]\nL40: }",
            "callId": "call_cTGE24akmteQx4x61R7GQD02"
          }
        ],
        "usage": {
          "promptTokens": 28528,
          "cachedTokens": 27648,
          "responseTokens": 137,
          "thinkingTokens": 845,
          "totalTokens": 29510
        },
        "costUsd": 0.0028752
      },
      {
        "step": 33,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/public_summary.json",
              "offset": 2,
              "limit": 1
            },
            "output": "L3:   \"plain_language_summary\": \"This study tested whether injecting mRNA vaccines directly into tumors can make cancers more visible to the immune system and improve responses to anti-PD-L1 therapy. In several mouse tumor models, the combination arm showed stronger evidence of immune activation than controls: broader antigen representation, stronger MHC-I peptide presentation, higher type I interferon response, increased PD-L1 expression, and higher intratumoral CD8+ T-cell density. Control analyse",
            "callId": "call_fZxiZurE4TyKQ9tTP3TMwx1B"
          }
        ],
        "usage": {
          "promptTokens": 31834,
          "cachedTokens": 28416,
          "responseTokens": 32,
          "thinkingTokens": 998,
          "totalTokens": 32864
        },
        "costUsd": 0.0036249
      },
      {
        "step": 34,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/study_overview.json",
              "offset": 0,
              "limit": 500
            },
            "output": "L1: {\nL2:   \"paper\": {\nL3:     \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\nL4:     \"doi\": \"10.1038/s41586-025-09006-8\",\nL5:     \"publication_year\": 2025,\nL6:     \"domain\": \"oncology-immunology\",\nL7:     \"study_type\": \"preclinical+retrospective\"\nL8:   },\nL9:   \"core_question\": \"Can intratumoral mRNA vaccination increase tumor immunogenicity and improve response to anti-PD-L1 immune checkpoint blockade in mice and in retrospective human ICI-treated patients?\",\nL10:   \"datasets_or_cohorts\": [\nL11:     {\nL12:       \"id\": \"mouse-efficacy-cohort\",\nL13:       \"label\": \"Mouse efficacy cohort\",\nL14:       \"sample_size_or_observations\": \"78 mice\",\nL15:       \"description\": \"Preclinical mice with tumor-bearing models receiving the combination therapy arm across pooled repeat experiments.\"\nL16:     },\nL17:     {\nL18:       \"id\": \"mouse-control-cohort\",\nL19:       \"label\": \"Mouse control cohort\",\nL20:       \"sample_size_or_observations\": \"84 mice\",\nL21:       \"description\": \"Matched preclinical controls (vaccine only, ICI only, and vehicle), pooled across repeat mouse experiments.\"\nL22:     },\nL23:     {\nL24:       \"id\": \"human-retrospective-cohort\",\nL25:       \"label\": \"Human retrospective cohort\",\nL26:       \"sample_size_or_observations\": \"130 patients\",\nL27:       \"description\": \"Retrospective cohort of metastatic patients receiving ICI, stratified by prior SARS-CoV-2 mRNA vaccination status.\"\nL28:     },\nL29:     {\nL30:       \"id\": \"human-vaccinated-subgroup\",\nL31:       \"label\": \"Human vaccinated subgroup\",\nL32:       \"sample_size_or_observations\": \"43 patients\",\nL33:       \"description\": \"Retrospective vaccinated subgroup within the human cohort used for survival comparison versus unvaccinated patients.\"\nL34:     },\nL35:     {\nL36:       \"id\": \"human-unvaccinated-subgroup\",\nL37:       \"label\": \"Human unvaccinated subgroup\",\nL38:       \"sample_size_or_observations\": \"87 patients\",\nL39:       \"description\": \"Retrospective unvaccinated comparator subgroup within the same ICI-treated metastatic patient cohort.\"\nL40:     }\nL41:   ],\nL42:   \"major_limitations\": [\nL43:     \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\nL44:     \"Vaccination timing relative to ICI initiation varied across patients in the retrospective human cohort.\",\nL45:     \"Tumor-type mix and prior treatment-history heterogeneity limit direct causal interpretation of outcomes.\",\nL46:     \"Mouse model effects may not map one-to-one to all human tumors.\",\nL47:     \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\nL48:   ]\nL49: }",
            "callId": "call_XOFnEFTHNKYiqM9htEXqr0Ar"
          }
        ],
        "usage": {
          "promptTokens": 31972,
          "cachedTokens": 31744,
          "responseTokens": 34,
          "thinkingTokens": 182,
          "totalTokens": 32188
        },
        "costUsd": 0.0012826
      },
      {
        "step": 35,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/study_overview.json",
              "offset": 0,
              "limit": 500
            },
            "output": "L1: {\nL2:   \"paper\": {\nL3:     \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\nL4:     \"doi\": \"10.1038/s41586-025-09006-8\",\nL5:     \"publication_year\": 2025,\nL6:     \"domain\": \"oncology-immunology\",\nL7:     \"study_type\": \"preclinical+retrospective\"\nL8:   },\nL9:   \"core_question\": \"Can intratumoral mRNA vaccination increase tumor immunogenicity and improve response to anti-PD-L1 immune checkpoint blockade in mice and in retrospective human ICI-treated patients?\",\nL10:   \"datasets_or_cohorts\": [\nL11:     {\nL12:       \"id\": \"mouse-efficacy-cohort\",\nL13:       \"label\": \"Mouse efficacy cohort\",\nL14:       \"sample_size_or_observations\": \"78 mice\",\nL15:       \"description\": \"Preclinical mice with tumor-bearing models receiving the combination therapy arm across pooled repeat experiments.\"\nL16:     },\nL17:     {\nL18:       \"id\": \"mouse-control-cohort\",\nL19:       \"label\": \"Mouse control cohort\",\nL20:       \"sample_size_or_observations\": \"84 mice\",\nL21:       \"description\": \"Matched preclinical controls (vaccine only, ICI only, and vehicle), pooled across repeat mouse experiments.\"\nL22:     },\nL23:     {\nL24:       \"id\": \"human-retrospective-cohort\",\nL25:       \"label\": \"Human retrospective cohort\",\nL26:       \"sample_size_or_observations\": \"130 patients\",\nL27:       \"description\": \"Retrospective cohort of metastatic patients receiving ICI, stratified by prior SARS-CoV-2 mRNA vaccination status.\"\nL28:     },\nL29:     {\nL30:       \"id\": \"human-vaccinated-subgroup\",\nL31:       \"label\": \"Human vaccinated subgroup\",\nL32:       \"sample_size_or_observations\": \"43 patients\",\nL33:       \"description\": \"Retrospective vaccinated subgroup within the human cohort used for survival comparison versus unvaccinated patients.\"\nL34:     },\nL35:     {\nL36:       \"id\": \"human-unvaccinated-subgroup\",\nL37:       \"label\": \"Human unvaccinated subgroup\",\nL38:       \"sample_size_or_observations\": \"87 patients\",\nL39:       \"description\": \"Retrospective unvaccinated comparator subgroup within the same ICI-treated metastatic patient cohort.\"\nL40:     }\nL41:   ],\nL42:   \"major_limitations\": [\nL43:     \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\nL44:     \"Vaccination timing relative to ICI initiation varied across patients in the retrospective human cohort.\",\nL45:     \"Tumor-type mix and prior treatment-history heterogeneity limit direct causal interpretation of outcomes.\",\nL46:     \"Mouse model effects may not map one-to-one to all human tumors.\",\nL47:     \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\nL48:   ]\nL49: }",
            "callId": "call_F4VCefW7jPRV5Gj7n8ZMWdgL"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "offset": 0,
              "limit": 700
            },
            "output": "L1: {\nL2:   \"findings\": [\nL3:     {\nL4:       \"id\": \"Q01\",\nL5:       \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\nL6:       \"value\": \"62.3%\",\nL7:       \"comparator_or_baseline\": \"37.3%\",\nL8:       \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination.\",\nL9:       \"evidence_line_refs\": [\"L28\"]\nL10:     },\nL11:     {\nL12:       \"id\": \"Q02\",\nL13:       \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\nL14:       \"value\": \"40.6%\",\nL15:       \"comparator_or_baseline\": \"20.6%\",\nL16:       \"interpretation\": \"Strong expansion of MHC-I-presented landscape.\",\nL17:       \"evidence_line_refs\": [\"L29\"]\nL18:     },\nL19:     {\nL20:       \"id\": \"Q03\",\nL21:       \"metric\": \"Retrospective human survival comparison p-value\",\nL22:       \"value\": \"p=0.01\",\nL23:       \"comparator_or_baseline\": \"N/A\",\nL24:       \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment.\",\nL25:       \"evidence_line_refs\": [\"L30\"]\nL26:     },\nL27:     {\nL28:       \"id\": \"Q04\",\nL29:       \"metric\": \"Type I interferon response score (normalized units)\",\nL30:       \"value\": \"3.1\",\nL31:       \"comparator_or_baseline\": \"1.0\",\nL32:       \"interpretation\": \"Marked induction after mRNA vaccination in tumors.\",\nL33:       \"evidence_line_refs\": [\"L31\"]\nL34:     },\nL35:     {\nL36:       \"id\": \"Q05\",\nL37:       \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\nL38:       \"value\": \"2.4x\",\nL39:       \"comparator_or_baseline\": \"1.0x\",\nL40:       \"interpretation\": \"Checkpoint axis became more targetable.\",\nL41:       \"evidence_line_refs\": [\"L32\"]\nL42:     },\nL43:     {\nL44:       \"id\": \"Q06\",\nL45:       \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\nL46:       \"value\": \"1.8x\",\nL47:       \"comparator_or_baseline\": \"1.0x\",\nL48:       \"interpretation\": \"Increased immune infiltration with combination therapy.\",\nL49:       \"evidence_line_refs\": [\"L33\"]\nL50:     }\nL51:   ],\nL52:   \"controls_or_null_results\": [\nL53:     {\nL54:       \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\nL55:       \"evidence_line_ref\": \"L36\"\nL56:     },\nL57:     {\nL58:       \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\nL59:       \"evidence_line_ref\": \"L37\"\nL60:     },\nL61:     {\nL62:       \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the observed sensitization effect.\",\nL63:       \"evidence_line_ref\": \"L38\"\nL64:     },\nL65:     {\nL66:       \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\nL67:       \"evidence_line_ref\": \"L39\"\nL68:     }\nL69:   ]\nL70: }",
            "callId": "call_cdUU4UaAbazfZDi2qF7SVw5B"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "offset": 0,
              "limit": 700
            },
            "output": "L1: {\nL2:   \"claims\": [\nL3:     {\nL4:       \"claim_id\": \"C01\",\nL5:       \"claim\": \"Intratumoral mRNA vaccination is proposed to increase tumor immunogenicity and improve anti-PD-L1 responses by expanding antigen presentation on MHC-I.\",\nL6:       \"strength\": \"moderate\",\nL7:       \"evidence\": [\nL8:         {\nL9:           \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\nL10:           \"line_ref\": \"L42\"\nL11:         },\nL12:         {\nL13:           \"quote\": \"A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\",\nL14:           \"line_ref\": \"L44\"\nL15:         }\nL16:       ],\nL17:       \"caveat\": \"The report notes that some mechanistic readouts were strongest in specific model systems, so effects may not be uniform across tumors.\"\nL18:     },\nL19:     {\nL20:       \"claim_id\": \"C02\",\nL21:       \"claim\": \"mRNA vaccination induces higher type I interferon activity in tumors than comparator conditions in the mouse experiments.\",\nL22:       \"strength\": \"strong\",\nL23:       \"evidence\": [\nL24:         {\nL25:           \"quote\": \"Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors\",\nL26:           \"line_ref\": \"L31\"\nL27:         },\nL28:         {\nL29:           \"quote\": \"Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination\",\nL30:           \"line_ref\": \"L28\"\nL31:         }\nL32:       ],\nL33:       \"caveat\": \"The table summarizes these values, and the report does not provide additional design details for each numerical comparison in this extract.\"\nL34:     },\nL35:     {\nL36:       \"claim_id\": \"C03\",\nL37:       \"claim\": \"Type I interferon signaling is necessary for the sensitization benefit in preclinical settings, because anti-IFNAR1 blockade abolished the benefit.\",\nL38:       \"strength\": \"strong\",\nL39:       \"evidence\": [\nL40:         {\nL41:           \"quote\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\nL42:           \"line_ref\": \"L39\"\nL43:         },\nL44:         {\nL45:           \"quote\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\nL46:           \"line_ref\": \"L38\"\nL47:         }\nL48:       ],\nL49:       \"caveat\": \"This is a mechanistic inference from preclinical perturbation controls and cannot by itself prove causality in patients.\"\nL50:     },\nL51:     {\nL52:       \"claim_id\": \"C04\",\nL53:       \"claim\": \"In the retrospective human cohort, prior SARS-CoV-2 mRNA vaccination was associated with improved survival under ICI treatment compared with no prior vaccination.\",\nL54:       \"strength\": \"tentative\",\nL55:       \"evidence\": [\nL56:         {\nL57:           \"quote\": \"Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment\",\nL58:           \"line_ref\": \"L30\"\nL59:         },\nL60:         {\nL61:           \"quote\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\nL62:           \"line_ref\": \"L49\"\nL63:         }\nL64:       ],\nL65:       \"caveat\": \"This analysis is retrospective with heterogeneous tumor types and variable vaccination timing, so unmeasured confounding may influence outcomes.\"\nL66:     }\nL67:   ]\nL68: }",
            "callId": "call_lD5dRHkU46dSviUAiOmHcJas"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/public_summary.json",
              "offset": 0,
              "limit": 700
            },
            "output": "L1: {\nL2:   \"headline\": \"Intratumoral mRNA vaccination may sensitize tumors to checkpoint blockade\",\nL3:   \"plain_language_summary\": \"This study tested whether injecting mRNA vaccines directly into tumors can make cancers more visible to the immune system and improve responses to anti-PD-L1 therapy. In several mouse tumor models, the combination arm showed stronger evidence of immune activation than controls: broader antigen representation, stronger MHC-I peptide presentation, higher type I interferon response, increased PD-L1 expression, and higher intratumoral CD8+ T-cell density. Control analyse\nL4:   \"what_is_new\": [\nL5:     \"The work links preclinical mechanistic studies to a human retrospective association in one translational framework.\",\nL6:     \"It reports a required role for type I interferon signaling, including loss of sensitization when anti-IFNAR1 is applied.\",\nL7:     \"The study documents coordinated quantitative changes in antigen presentation, interferon signaling, PD-L1, and T-cell infiltration with intratumoral mRNA vaccination.\"\nL8:   ],\nL9:   \"why_caution_is_needed\": [\nL10:     \"The human analysis is retrospective and non-randomized, so confounding can affect apparent survival differences.\",\nL11:     \"Vaccination timing relative to ICI initiation varied across patients and may influence apparent benefit.\",\nL12:     \"The retrospective cohort was heterogeneous in tumor types and treatment histories, limiting direct causal interpretation.\",\nL13:     \"Mouse-model findings may not translate equally across all human cancers.\",\nL14:     \"Some mechanistic readouts were strongest only in specific models rather than uniformly across all tests.\"\nL15:   ],\nL16:   \"glossary\": [\nL17:     {\nL18:       \"term\": \"mRNA vaccine\",\nL19:       \"definition\": \"A therapy that uses messenger RNA to direct cells to make proteins and trigger local immune activation.\"\nL20:     },\nL21:     {\nL22:       \"term\": \"PD-L1\",\nL23:       \"definition\": \"A checkpoint protein that can suppress T-cell killing; blocking it can increase anti-tumor immune activity.\"\nL24:     },\nL25:     {\nL26:       \"term\": \"ICI\",\nL27:       \"definition\": \"Immune checkpoint inhibitor, a drug class that releases brakes on immune cells to improve anti-cancer responses.\"\nL28:     },\nL29:     {\nL30:       \"term\": \"Retrospective cohort\",\nL31:       \"definition\": \"A study of existing patient records where treatment groups are compared after care has already occurred.\"\nL32:     }\nL33:   ],\nL34:   \"open_questions\": [\nL35:     \"Can these tumor-sensitization effects be reproduced in randomized human trials with preplanned timing and endpoints?\",\nL36:     \"Which tumor types and clinical settings are most likely to benefit from intratumoral mRNA sensitization?\",\nL37:     \"Can biomarkers of interferon signaling or antigen presentation identify likely responders before treatment?\",\nL38:     \"What are the durability and safety implications of combining intratumoral mRNA with checkpoint blockade over longer follow-up?\"\nL39:   ]\nL40: }",
            "callId": "call_1ifrPabqoa9DsRknAS1j2Pcx"
          }
        ],
        "usage": {
          "promptTokens": 32718,
          "cachedTokens": 31872,
          "responseTokens": 133,
          "thinkingTokens": 177,
          "totalTokens": 33028
        },
        "costUsd": 0.0016283
      },
      {
        "step": 36,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "grep_search",
            "input": {
              "pattern": "Control",
              "dir_path": "output",
              "include": "public_summary.json",
              "exclude_pattern": null,
              "names_only": null,
              "max_matches_per_file": 20,
              "total_max_matches": 20
            },
            "output": "output/public_summary.json:3:  \"plain_language_summary\": \"This study tested whether injecting mRNA vaccines directly into tumors can make cancers more visible to the immune system and improve responses to anti-PD-L1 therapy. In several mouse tumor models, the combination arm showed stronger evidence of immune activation than controls: broader antigen representation, stronger MHC-I peptide presentation, higher type I interferon response, increased PD-L1 expression, and higher intratumoral CD8+ T-cell density. Control analyses reported limited benefit in vaccine-only or ICI-only settings and loss of effect when type I interferon signaling was blocked, supporting a mechanistic pathway. In a retrospective cohort of 130 metastatic patients treated with ICIs, 43 had prior SARS-CoV-2 mRNA vaccination and 87 had not, with a reported survival p-value of 0.01 favoring the vaccinated subgroup. The authors therefore propose a translational sensitization strategy but stress that retrospective, non-randomized evidence is not sufficient to change clinical protocols without prospective randomized confirmation.\",",
            "callId": "call_WF4oncu3ooCNtfTp3ZwBQUxt"
          }
        ],
        "usage": {
          "promptTokens": 36020,
          "cachedTokens": 32640,
          "responseTokens": 55,
          "thinkingTokens": 470,
          "totalTokens": 36545
        },
        "costUsd": 0.002711
      },
      {
        "step": 37,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/public_summary.json",
              "offset": 0,
              "limit": 2000
            },
            "output": "L1: {\nL2:   \"headline\": \"Intratumoral mRNA vaccination may sensitize tumors to checkpoint blockade\",\nL3:   \"plain_language_summary\": \"This study tested whether injecting mRNA vaccines directly into tumors can make cancers more visible to the immune system and improve responses to anti-PD-L1 therapy. In several mouse tumor models, the combination arm showed stronger evidence of immune activation than controls: broader antigen representation, stronger MHC-I peptide presentation, higher type I interferon response, increased PD-L1 expression, and higher intratumoral CD8+ T-cell density. Control analyse\nL4:   \"what_is_new\": [\nL5:     \"The work links preclinical mechanistic studies to a human retrospective association in one translational framework.\",\nL6:     \"It reports a required role for type I interferon signaling, including loss of sensitization when anti-IFNAR1 is applied.\",\nL7:     \"The study documents coordinated quantitative changes in antigen presentation, interferon signaling, PD-L1, and T-cell infiltration with intratumoral mRNA vaccination.\"\nL8:   ],\nL9:   \"why_caution_is_needed\": [\nL10:     \"The human analysis is retrospective and non-randomized, so confounding can affect apparent survival differences.\",\nL11:     \"Vaccination timing relative to ICI initiation varied across patients and may influence apparent benefit.\",\nL12:     \"The retrospective cohort was heterogeneous in tumor types and treatment histories, limiting direct causal interpretation.\",\nL13:     \"Mouse-model findings may not translate equally across all human cancers.\",\nL14:     \"Some mechanistic readouts were strongest only in specific models rather than uniformly across all tests.\"\nL15:   ],\nL16:   \"glossary\": [\nL17:     {\nL18:       \"term\": \"mRNA vaccine\",\nL19:       \"definition\": \"A therapy that uses messenger RNA to direct cells to make proteins and trigger local immune activation.\"\nL20:     },\nL21:     {\nL22:       \"term\": \"PD-L1\",\nL23:       \"definition\": \"A checkpoint protein that can suppress T-cell killing; blocking it can increase anti-tumor immune activity.\"\nL24:     },\nL25:     {\nL26:       \"term\": \"ICI\",\nL27:       \"definition\": \"Immune checkpoint inhibitor, a drug class that releases brakes on immune cells to improve anti-cancer responses.\"\nL28:     },\nL29:     {\nL30:       \"term\": \"Retrospective cohort\",\nL31:       \"definition\": \"A study of existing patient records where treatment groups are compared after care has already occurred.\"\nL32:     }\nL33:   ],\nL34:   \"open_questions\": [\nL35:     \"Can these tumor-sensitization effects be reproduced in randomized human trials with preplanned timing and endpoints?\",\nL36:     \"Which tumor types and clinical settings are most likely to benefit from intratumoral mRNA sensitization?\",\nL37:     \"Can biomarkers of interferon signaling or antigen presentation identify likely responders before treatment?\",\nL38:     \"What are the durability and safety implications of combining intratumoral mRNA with checkpoint blockade over longer follow-up?\"\nL39:   ]\nL40: }",
            "callId": "call_4eakiL6HgUgXdOto66NWRFjB"
          }
        ],
        "usage": {
          "promptTokens": 36297,
          "cachedTokens": 35840,
          "responseTokens": 33,
          "thinkingTokens": 264,
          "totalTokens": 36594
        },
        "costUsd": 0.0016042500000000002
      },
      {
        "step": 38,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "grep_search",
            "input": {
              "pattern": "Control analyses reported limited benefit",
              "dir_path": "output",
              "include": "public_summary.json",
              "exclude_pattern": null,
              "names_only": null,
              "max_matches_per_file": 20,
              "total_max_matches": 20
            },
            "output": "output/public_summary.json:3:  \"plain_language_summary\": \"This study tested whether injecting mRNA vaccines directly into tumors can make cancers more visible to the immune system and improve responses to anti-PD-L1 therapy. In several mouse tumor models, the combination arm showed stronger evidence of immune activation than controls: broader antigen representation, stronger MHC-I peptide presentation, higher type I interferon response, increased PD-L1 expression, and higher intratumoral CD8+ T-cell density. Control analyses reported limited benefit in vaccine-only or ICI-only settings and loss of effect when type I interferon signaling was blocked, supporting a mechanistic pathway. In a retrospective cohort of 130 metastatic patients treated with ICIs, 43 had prior SARS-CoV-2 mRNA vaccination and 87 had not, with a reported survival p-value of 0.01 favoring the vaccinated subgroup. The authors therefore propose a translational sensitization strategy but stress that retrospective, non-randomized evidence is not sufficient to change clinical protocols without prospective randomized confirmation.\",",
            "callId": "call_fKkHJMjkp7HpZdHXj8vX7Piy"
          }
        ],
        "usage": {
          "promptTokens": 37022,
          "cachedTokens": 36096,
          "responseTokens": 60,
          "thinkingTokens": 705,
          "totalTokens": 37787
        },
        "costUsd": 0.0026639
      },
      {
        "step": 39,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "text": "- [x] `output/study_overview.json`  \n- [x] `output/quantitative_findings.json`  \n- [x] `output/claim_audit.json`  \n- [x] `output/public_summary.json`",
        "toolCalls": [],
        "usage": {
          "promptTokens": 37303,
          "cachedTokens": 36864,
          "responseTokens": 56,
          "thinkingTokens": 2290,
          "totalTokens": 39649
        },
        "costUsd": 0.00572335
      }
    ],
    "totalCostUsd": 0.09959579999999998
  }
}
